header logo image


Page 907«..1020..906907908909..920930..»

Third eye – Wikipedia

June 30th, 2018 1:42 am

The third eye (also called the mind's eye, or inner eye) is a mystical and esoteric concept of a speculative invisible eye which provides perception beyond ordinary sight.[1]

In certain dharmic spiritual traditions the third eye refers to the ajna (or brow) chakra.[2] The third eye refers to the gate that leads to inner realms and spaces of higher consciousness. In New Age spirituality, the third eye often symbolizes a state of enlightenment or the evocation of mental images having deeply personal spiritual or psychological significance. The third eye is often associated with religious visions, clairvoyance, the ability to observe chakras and auras,[3] precognition, and out-of-body experiences. People who are claimed to have the capacity to utilize their third eyes are sometimes known as seers. In some traditions such as Hinduism, the third eye is said to be located around the middle of the forehead, slightly above the junction of the eyebrows.

In Taoism and many traditional Chinese religious sects such as Chan (called Zen in Japanese), "third eye training" involves focusing attention on the point between the eyebrows with the eyes closed, and while the body is in various qigong postures. The goal of this training is to allow students to tune into the correct "vibration" of the universe and gain a solid foundation on which to reach more advanced meditation levels. Taoism teaches that the third eye, also called the mind's eye, is situated between the two physical eyes, and expands up to the middle of the forehead when opened. Taoism claims that the third eye is one of the main energy centers of the body located at the sixth Chakra, forming a part of the main meridian, the line separating left and right hemispheres of the body.[4] In Taoist alchemical traditions, the third eye is the frontal part of the "Upper Dan Tien" (upper cinnabar field) and is given the evocative name "muddy pellet".

According to the Christian teaching of Father Richard Rohr, the concept of the third eye is a metaphor for non-dualistic thinking; the way the mystics see. In Rohr's concept, mystics employ the first eye (sensory input such as sight) and the second eye (the eye of reason, meditation, and reflection), "but they know not to confuse knowledge with depth, or mere correct information with the transformation of consciousness itself. The mystical gaze builds upon the first two eyesand yet goes further." Rohr refers to this level of awareness as "having the mind of Christ".[5]

In Theosophy it is related to the pineal gland.[6] According to this belief, humans had in far ancient times an actual third eye in the back of the head with a physical and spiritual function. Over time, as humans evolved, this eye atrophied and sunk into what today is known as the pineal gland.[6] Dr. Rick Strassman has hypothesized that the pineal gland, which maintains light sensitivity, is responsible for the production and release of DMT (dimethyltryptamine), an entheogen which he believes possibly could be excreted in large quantities at the moments of birth and death.[7]

Adherents of theosophist H.P. Blavatsky[8] have suggested that the third eye is in fact the partially dormant pineal gland, which resides between the two hemispheres of the brain. Reptiles and amphibians sense light via a third parietal eyea structure associated with the pineal glandwhich serves to regulate their circadian rhythms, and for navigation, as it can sense the polarization of light. C.W. Leadbeater claimed that by extending an "etheric tube" from the third eye, it is possible to develop microscopic and telescopic vision.[3] It has been asserted by Stephen Phillips that the third eye's microscopic vision is capable of observing objects as small as quarks.[9]

The use of the phrase mind's eye does not imply that there is a single or unitary place in the mind or brain where visual consciousness occurs. Philosophers such as Daniel Dennett have critiqued this view.[10] However, others, such as Johnjoe McFadden of the University of Surrey in the United Kingdom and the New Zealand-based neurobiologist Susan Pockett, propose that the brain's electromagnetic field is consciousness itself, thus causing the perception of a unitary location.[11][12]

Here is the original post:
Third eye - Wikipedia

Read More...

The Immune System Explained I Bacteria Infection – YouTube

June 30th, 2018 1:41 am

Every second of your life you are under attack. Bacteria, viruses, spores and more living stuff wants to enter your body and use its resources for itself. The immune system is a powerful army of cells that fights like a T-Rex on speed and sacrifices itself for your survival. Without it you would die in no time. This sounds simple but the reality is complex, beautiful and just awesome. An animation of the immune system.

We are thinking of making an App for tablets out of this video. Would you like that? Did you think the visual system we developed worked? Feedback is much appreciated!

You can get the MUSIC of the video here: http://thomasveith.bandcamp.com/track...

Videos, explaining things. Like evolution, time, space, global energy or our existence in this strange universe. We are a team of designers, journalists and musicians who want to make science look beautiful. Because it is beautiful.

Visit us on our Website, Twitter, Facebook, Patreon or Behance to say hi!

https://www.facebook.com/Kurzgesagthttps://twitter.com/Kurz_Gesagthttp://kurzgesagt.orghttp://www.patreon.com/Kurzgesagthttp://www.behance.net/kurzgesagt

THANKS A LOT TO OUR PATRONS FOR SUPPORTING US:

Justin Degenaarsjordan gardnerDerek LoaJeroen KoertsCarlos CampuzanoBenot GrahamScott ZellTanya SmirnovaGiovanna CardosoPatrick EyrichAlex KaplanChris DudleyDeanie AdamsCaroline AndrewesDean HerbertRory BennettAdam PrimaerosRasmus LindDaniel O.C.L.Dylan HofferMaxl HeitschEliud VasquezNeve LaugheryGhitea Andrei PaulAlexander Law McCormack HeavensEduardo BarbosaSara Shah Dario Pagnia Chris Doughty Evan Low Stephen MorseBnyamin TetikRomano Casellinidante harperJustin T.Greeny Liu Siddharth Bajaj Valerie Brunet Jen Tim Peter Wagner YousifEfe Melih PolatGatanMaximilian RitterCharles Kuang Balazs-Hegedus JozsefPetr PilaFinn EdwardsThomas LeeDaniel FuchsPascal B.Seona TeaPol LutgenRoman ZolotorevichDaniel Jonathan Velazquez GoreJeff "Church" ChurchillRandy KnappBrandon LiuPeter nuderlSwarochisha KandregulaJavier de la GarzaJan Lukas Lehmann somersault18:24

Why you are still alive - The immune system explained

Help us caption & translate this video!

http://www.youtube.com/timedtext_cs_p...

Read the rest here:
The Immune System Explained I Bacteria Infection - YouTube

Read More...

About Dr. Rimma Sherman | Integrative Medicine of New Jersey

June 30th, 2018 1:41 am

About Dr. Rimma Sherman

I was raised in Eastern Europe among a family of physicians. Remembering my childhood, as far back as when I was only ve years old, I can still vividly recall accompanying my mother as she visited her private patients. The relationship-centered care she provided fascinated me. I could see that my mothers patients beneted greatly just from exposure to her grace and kindness. The European model of medical care I was exposed to was holistic encompassing much more than just prescription writing. In fact my mothers advice to her patients frequently drew from naturopathic medical knowledge.

As I grew up, a few instances of the holistic approach to patient care I witnessed as a child were particularly memorable. Still living in Eastern Europe, I recall when my newborn rst niece developed some problems that were relieved solely through lifestyle and dietary modications. When my older daughter was an infant and I began supplementing breast feeding with regular food, she began to suffer from bouts of diarrhea. Based upon advice from my pediatrician grandmother, I made a few simple modications to my daughters diet and her issues with diarrhea were solved.

In 1988 I moved to the United States, and became a licensed physician in 1993. Two years later, in 1995,1 commenced my residency. Throughout my professional career, I have always adhered to a model of practicing medicine where I look to treat the whole person, employing a holistic approach rst and without harm. I believe in a personal and caring relationship with my patients and derive great satisfaction from providing this type of patient-doctor connection.

Ten years ago when my father became sick with cancer, I started an intense study of the spiritual aspect of human existence along with physical, environmental, mental, emotional and social experiences. Unfortunately, my fathers cancer took his life before I had the chance to offer him the benet of my learning. Even though I could not help my father, my unique course of studies directly benet my current patients. I am condent that my many and varied acquired experiences, tempered by my emotional maturation, and are helping my patients today.

In todays world the business aspects of medicine are becoming increasingly difcult, yet these difculties seem small, almost negligible, when I am greeted by my many happy patients coming back to me with gratitude and their kind appreciation. It is clear to me that when simple holistic measures help heal body, mind and spirit, it really makes a huge difference in peoples lives.

Over many years of practicing Internal Medicine in my small private practice in Central New Jersey, I have slowly changed the way my patients think about medicine and disease. Initially, and without scaring them, I asked my patients if they would be open to trying some natural ways of healing. Even in the situations where I recommend a more traditional medical course of treatment, my patients always ask if I have something more natural to offer them.

Reective of how I have developed my practice of medicine, earlier this year I changed the name of my practice from Rimma Sherman, M.D., P.C. toIntegrativeMedicine of New Jersey and am now a member of the American College of Nutrition.

Chance favors the prepared mind. ~Louis Pasteur

Integrative Medicine New Jersey

Dr. Rimma Sherman

Allergy Doctor West Orange, NJ

Integrative Medicine New Jersey

Dr. Rimma Sherman

Allergy Doctor West Orange, NJ

See the rest here:
About Dr. Rimma Sherman | Integrative Medicine of New Jersey

Read More...

T cell – Wikipedia

June 29th, 2018 12:44 am

A T cell, or T lymphocyte, is a type of lymphocyte (a subtype of white blood cell) that plays a central role in cell-mediated immunity. T cells can be distinguished from other lymphocytes, such as B cells and natural killer cells, by the presence of a T-cell receptor on the cell surface. They are called T cells because they mature in the thymus from thymocytes[1] (although some also mature in the tonsils[2]). The several subsets of T cells each have a distinct function. The majority of human T cells rearrange their alpha and beta chains on the cell receptor and are termed alpha beta T cells ( T cells) and are part of the adaptive immune system. Specialized gamma delta T cells, (a small minority of T cells in the human body, more frequent in ruminants), have invariant T-cell receptors with limited diversity, that can effectively present antigens to other T cells[3] and are considered to be part of the innate immune system.

Effector cells are the superset of all the various T cell types that actively respond immediately to a stimulus, such as co-stimulation. This includes helper, killer, regulatory, and potentially other T cell types. Memory cells are their opposite counterpart that are longer lived to target future infections as necessary.

T helper cells (TH cells) assist other white blood cells in immunologic processes, including maturation of B cells into plasma cells and memory B cells, and activation of cytotoxic T cells and macrophages. These cells are also known as CD4+ T cells because they express the CD4 glycoprotein on their surfaces. Helper T cells become activated when they are presented with peptide antigens by MHC class II molecules, which are expressed on the surface of antigen-presenting cells (APCs). Once activated, they divide rapidly and secrete small proteins called cytokines that regulate or assist in the active immune response. These cells can differentiate into one of several subtypes, including TH1, TH2, TH3, TH17, TH9, or TFH, which secrete different cytokines to facilitate different types of immune responses. Signalling from the APC directs T cells into particular subtypes.[4]

Cytotoxic T cells (TC cells, CTLs, T-killer cells, killer T cells) destroy virus-infected cells and tumor cells, and are also implicated in transplant rejection. These cells are also known as CD8+ T cells since they express the CD8 glycoprotein at their surfaces. These cells recognize their targets by binding to antigen associated with MHC class I molecules, which are present on the surface of all nucleated cells. Through IL-10, adenosine, and other molecules secreted by regulatory T cells, the CD8+ cells can be inactivated to an anergic state, which prevents autoimmune diseases.

Antigen-nave T cells expand and differentiate into memory and effector T cells after they encounter their cognate antigen within the context of an MHC molecule on the surface of a professional antigen presenting cell (e.g. a dendritic cell). Appropriate co-stimulation must be present at the time of antigen encounter for this process to occur. Historically, memory T cells were thought to belong to either the effector or central memory subtypes, each with their own distinguishing set of cell surface markers (see below).[5] Subsequently, numerous new populations of memory T cells were discovered including tissue-resident memory T (Trm) cells, stem memory TSCM cells, and virtual memory T cells. The single unifying theme for all memory T cell subtypes is that they are long-lived and can quickly expand to large numbers of effector T cells upon re-exposure to their cognate antigen. By this mechanism they provide the immune system with "memory" against previously encountered pathogens. Memory T cells may be either CD4+ or CD8+ and usually express CD45RO.[6]

Memory T cell subtypes:

Regulatory T cells (suppressor T cells) are crucial for the maintenance of immunological tolerance. Their major role is to shut down T cell-mediated immunity toward the end of an immune reaction and to suppress autoreactive T cells that escaped the process of negative selection in the thymus. Suppressor T cells along with Helper T cells can collectively be called Regulatory T cells due to their regulatory functions.[12]

Two major classes of CD4+ Treg cells have been described FOXP3+ Treg cells and FOXP3 Treg cells.

Regulatory T cells can develop either during normal development in the thymus, and are then known as thymic Treg cells, or can be induced peripherally and are called peripherally derived Treg cells. These two subsets were previously called "naturally occurring", and "adaptive" or "induced", respectively.[13] Both subsets require the expression of the transcription factor FOXP3 which can be used to identify the cells. Mutations of the FOXP3 gene can prevent regulatory T cell development, causing the fatal autoimmune disease IPEX.

Several other types of T cell have suppressive activity, but do not express FOXP3. These include Tr1 cells and Th3 cells, which are thought to originate during an immune response and act by producing suppressive molecules. Tr1 cells are associated with IL-10, and Th3 cells are associated with TGF-beta. Recently, Treg17 cells have been added to this list.[14]

Natural killer T cells (NKT cells not to be confused with natural killer cells of the innate immune system) bridge the adaptive immune system with the innate immune system. Unlike conventional T cells that recognize peptide antigens presented by major histocompatibility complex (MHC) molecules, NKT cells recognize glycolipid antigen presented by a molecule called CD1d. Once activated, these cells can perform functions ascribed to both Th and Tc cells (i.e., cytokine production and release of cytolytic/cell killing molecules). They are also able to recognize and eliminate some tumor cells and cells infected with herpes viruses.[15]

MAIT cells display innate, effector-like qualities.[16][17] In humans, MAIT cells are found in the blood, liver, lungs, and mucosa, defending against microbial activity and infection.[16] The MHC class I-like protein, MR1, is responsible for presenting bacterially-produced vitamin B metabolites to MAIT cells.[18][19][20] After the presentation of foreign antigen by MR1, MAIT cells secretes pro-inflammatory cytokines and are capable of lysing bacterially-infected cells.[16][20] MAIT cells can also be activated through MR1-independent signaling.[20] In addition to possessing innate-like functions, this T cell subset supports the adaptive immune response and has a memory-like phenotype.[16] Furthermore, MAIT cells are thought to play a role in autoimmune diseases, such as multiple sclerosis, arthritis and inflammatory bowel disease,[21][22] although definitive evidence is yet to be published.[23][24][25][26]

Gamma delta T cells ( T cells) represent a small subset of T cells that possess a distinct T cell receptor (TCR) on their surfaces. A majority of T cells have a TCR composed of two glycoprotein chains called - and - TCR chains. However, in T cells, the TCR is made up of one -chain and one -chain. This group of T cells is much less common in humans and mice (about 2% of total T cells); and are found mostly in the gut mucosa, within a population of lymphocytes known as intraepithelial lymphocytes. In rabbits, sheep, and chickens, the number of T cells can be as high as 60% of total T cells. The antigenic molecules that activate T cells are still widely unknown. However, T cells are not MHC-restricted and seem to be able to recognize whole proteins rather than requiring peptides to be presented by MHC molecules on APCs. Some murine T cells recognize MHC class IB molecules, though. Human V9/V2 T cells, which constitute the major T cell population in peripheral blood, are unique in that they specifically and rapidly respond to a set of nonpeptidic phosphorylated isoprenoid precursors, collectively named phosphoantigens, which are produced by virtually all living cells. The most common phosphoantigens from animal and human cells (including cancer cells) are isopentenyl pyrophosphate (IPP) and its isomer dimethylallyl pyrophosphate (DMPP). Many microbes produce the highly active compound hydroxy-DMAPP (HMB-PP) and corresponding mononucleotide conjugates, in addition to IPP and DMAPP. Plant cells produce both types of phosphoantigens. Drugs activating human V9/V2 T cells comprise synthetic phosphoantigens and aminobisphosphonates, which upregulate endogenous IPP/DMAPP.

All T cells originate from haematopoietic stem cells in the bone marrow. Haematopoietic progenitors (lymphoid progenitor cells) from haematopoietic stem cells populate the thymus and expand by cell division to generate a large population of immature thymocytes.[27] The earliest thymocytes express neither CD4 nor CD8, and are therefore classed as double-negative (CD4CD8) cells. As they progress through their development, they become double-positive thymocytes (CD4+CD8+), and finally mature to single-positive (CD4+CD8 or CD4CD8+) thymocytes that are then released from the thymus to peripheral tissues. There is some evidence of double-positive T-cells in the periphery, though their prevalence and function is uncertain.[28][29] In laboratory, T-cells can be converted into functional neurons within three weeks. [30]

About 98% of thymocytes die during the development processes in the thymus by failing either positive selection or negative selection, whereas the other 2% survive and leave the thymus to become mature immunocompetent T cells. Increasing evidence indicates microRNAs, which are small noncoding regulatory RNAs, could impact the clonal selection process during thymic development. For example, miR-181a was found to play a role in the positive selection of T lymphocytes.[31]

The thymus contributes fewer cells as a person ages. As the thymus shrinks by about 3%[32] a year throughout middle age, a corresponding fall in the thymic production of nave T cells occurs, leaving peripheral T cell expansion to play a greater role in protecting older subjects.

Common lymphoid precursor cells that migrate to the thymus become known as T-cell precursors (or thymocytes) and do not express a T cell receptor. Broadly speaking, the double negative (DN) stage is focused on producing a functional -chain whereas the double positive (DP) stage is focused on producing a functional -chain, ultimately producing a functional T cell receptor. As the developing thymocyte progresses through the four DN stages (DN1, DN2, DN3, and DN4), the T cell expresses an invariant -chain but rearranges the -chain locus. If the rearranged -chain successfully pairs with the invariant -chain, signals are produced which cease rearrangement of the -chain (and silence the alternate allele) and result in proliferation of the cell.[33] Although these signals require this pre-TCR at the cell surface, they are independent of ligand binding to the pre-TCR. These thymocytes will then express both CD4 and CD8 and progresses to the double positive (DP) stage where selection of the -chain takes place. If a rearranged -chain does not lead to any signalling (e.g. as a result of an inability to pair with the invariant -chain), the cell may die by neglect (lack of signalling).

Positive selection "selects for" T cells capable of interacting with MHC. Positive selection involves the production of a signal by double-positive precursors that express either MHC Class I or II restricted receptors. The signal produced by these thymocytes result in RAG gene repression, long-term survival and migration into the medulla, as well as differentiation into mature T cells. The process of positive selection takes a number of days.[34]

Double-positive thymocytes (CD4+/CD8+) move deep into the thymic cortex, where they are presented with self-antigens. These self-antigens are expressed by thymic cortical epithelial cells on MHC molecules on the surface of cortical epithelial cells. Only those thymocytes that interact with MHC-I or MHC-II appropriately (i.e., not too strongly or too weakly) will receive a vital "survival signal". All that cannot (i.e., if they do not interact strongly enough, or if they bind too strongly) will die by "death by neglect" (no survival signal). This process ensures that the selected T-cells will have an MHC affinity that can serve useful functions in the body (i.e., the cells must be able to interact with MHC and peptide complexes to effect immune responses). The vast majority of all thymocytes will die during this process.

A thymocyte's fate is determined during positive selection. Double-positive cells (CD4+/CD8+) that interact well with MHC class II molecules will eventually become CD4+ cells, whereas thymocytes that interact well with MHC class I molecules mature into CD8+ cells. A T cell becomes a CD4+ cell by down-regulating expression of its CD8 cell surface receptors. If the cell does not lose its signal, it will continue downregulating CD8 and become a CD4+, single positive cell.[35] But, if there is a signal interruption, the cell stops downregulating CD8 and switches over to downregulating CD4 molecules, instead, eventually becoming a CD8+, single positive cell.

This process does not remove thymocytes that may cause autoimmunity. The potentially autoimmune cells are removed by the process of negative selection, which occurs in the thymic medulla (discussed below).

Negative selection removes thymocytes that are capable of strongly binding with "self" MHC peptides. Thymocytes that survive positive selection migrate towards the boundary of the cortex and medulla in the thymus. While in the medulla, they are again presented with a self-antigen presented on the MHC complex of medullary thymic epithelial cells (mTECs).[36] mTECs must be AIRE+ to properly express self-antigens from all tissues of the body on their MHC class I peptides. Some mTECs are phagocytosed by thymic dendritic cells; this allows for presentation of self-antigens on MHC class II molecules (positively selected CD4+ cells must interact with MHC class II molecules, thus APCs, which possess MHC class II, must be present for CD4+ T-cell negative selection). Thymocytes that interact too strongly with the self-antigen receive an apoptotic signal that leads to cell death. However, some of these cells are selected to become Treg cells. The remaining cells exit the thymus as immature nave T cells (also known as recent thymic emigrants [37]). This process is an important component of central tolerance and serves to prevent the formation of self-reactive T cells that are capable of inducing autoimmune diseases in the host.

In summary, -selection is the first checkpoint, where the T cells that are able to form a functional pre-TCR with an invariant alpha chain and a functional beta chain are allowed to continue development in the thymus. Next, positive selection checks that T cells have successfully rearranged their TCR locus and are capable of recognizing peptide-MHC complexes with appropriate affinity. Negative selection in the medulla then obliterates T cells that bind too strongly to self-antigens expressed on MHC molecules. These selection processes allow for tolerance of self by the immune system. Typical T cells that leave the thymus (via the corticomedullarly junction) are self-restricted, self-tolerant, and singly positive.

Activation of CD4+ T cells occurs through the simultaneous engagement of the T-cell receptor and a co-stimulatory molecule (like CD28, or ICOS) on the T cell by the major histocompatibility complex (MHCII) peptide and co-stimulatory molecules on the APC. Both are required for production of an effective immune response; in the absence of co-stimulation, T cell receptor signalling alone results in anergy. The signalling pathways downstream from co-stimulatory molecules usually engages the PI3K pathway generating PIP3 at the plasma membrane and recruiting PH domain containing signaling molecules like PDK1 that are essential for the activation of PKC, and eventual IL-2 production. Optimal CD8+ T cell response relies on CD4+ signalling.[39] CD4+ cells are useful in the initial antigenic activation of nave CD8 T cells, and sustaining memory CD8+ T cells in the aftermath of an acute infection. Therefore, activation of CD4+ T cells can be beneficial to the action of CD8+ T cells.[40][41][42]

The first signal is provided by binding of the T cell receptor to its cognate peptide presented on MHCII on an APC. MHCII is restricted to so-called professional antigen-presenting cells, like dendritic cells, B cells, and macrophages, to name a few. The peptides presented to CD8+ T cells by MHC class I molecules are 813 amino acids in length; the peptides presented to CD4+ cells by MHC class II molecules are longer, usually 1225 amino acids in length,[43] as the ends of the binding cleft of the MHC class II molecule are open.

The second signal comes from co-stimulation, in which surface receptors on the APC are induced by a relatively small number of stimuli, usually products of pathogens, but sometimes breakdown products of cells, such as necrotic-bodies or heat shock proteins. The only co-stimulatory receptor expressed constitutively by nave T cells is CD28, so co-stimulation for these cells comes from the CD80 and CD86 proteins, which together constitute the B7 protein, (B7.1 and B7.2, respectively) on the APC. Other receptors are expressed upon activation of the T cell, such as OX40 and ICOS, but these largely depend upon CD28 for their expression. The second signal licenses the T cell to respond to an antigen. Without it, the T cell becomes anergic, and it becomes more difficult for it to activate in future. This mechanism prevents inappropriate responses to self, as self-peptides will not usually be presented with suitable co-stimulation. Once a T cell has been appropriately activated (i.e. has received signal one and signal two) it alters its cell surface expression of a variety of proteins. Markers of T cell activation include CD69, CD71 and CD25 (also a marker for Treg cells), and HLA-DR (a marker of human T cell activation). CTLA-4 expression is also up-regulated on activated T cells, which in turn outcompetes CD28 for binding to the B7 proteins. This is a checkpoint mechanism to prevent over activation of the T cell. Activated T cells also change their cell surface glycosylation profile.[44]

The T cell receptor exists as a complex of several proteins. The actual T cell receptor is composed of two separate peptide chains, which are produced from the independent T cell receptor alpha and beta (TCR and TCR) genes. The other proteins in the complex are the CD3 proteins: CD3 and CD3 heterodimers and, most important, a CD3 homodimer, which has a total of six ITAM motifs. The ITAM motifs on the CD3 can be phosphorylated by Lck and in turn recruit ZAP-70. Lck and/or ZAP-70 can also phosphorylate the tyrosines on many other molecules, not least CD28, LAT and SLP-76, which allows the aggregation of signalling complexes around these proteins.

Phosphorylated LAT recruits SLP-76 to the membrane, where it can then bring in PLC-, VAV1, Itk and potentially PI3K. PLC- cleaves PI(4,5)P2 on the inner leaflet of the membrane to create the active intermediaries diacylglycerol (DAG), inositol-1,4,5-trisphosphate (IP3); PI3K also acts on PIP2, phosphorylating it to produce phosphatidlyinositol-3,4,5-trisphosphate (PIP3). DAG binds and activates some PKCs. Most important in T cells is PKC, critical for activating the transcription factors NF-B and AP-1. IP3 is released from the membrane by PLC- and diffuses rapidly to activate calcium channel receptors on the ER, which induces the release of calcium into the cytosol. Low calcium in the endoplasmic reticulum causes STIM1 clustering on the ER membrane and leads to activation of cell membrane CRAC channels that allows additional calcium to flow into the cytosol from the extracellular space. This aggregated cytosolic calcium binds calmodulin, which can then activate calcineurin. Calcineurin, in turn, activates NFAT, which then translocates to the nucleus. NFAT is a transcription factor that activates the transcription of a pleiotropic set of genes, most notable, IL-2, a cytokine that promotes long-term proliferation of activated T cells.

PLC can also initiate the NF-B pathway. DAG activates PKC, which then phosphorylates CARMA1, causing it to unfold and function as a scaffold. The cytosolic domains bind an adapter BCL10 via CARD (Caspase activation and recruitment domains) domains; that then binds TRAF6, which is ubiquitinated at K63.:513523[45] This form of ubiquitination does not lead to degradation of target proteins. Rather, it serves to recruit NEMO, IKK and -, and TAB1-2/ TAK1.[46] TAK 1 phosphorylates IKK-, which then phosphorylates IB allowing for K48 ubiquitination: leads to proteasomal degradation. Rel A and p50 can then enter the nucleus and bind the NF-B response element. This coupled with NFAT signaling allows for complete activation of the IL-2 gene.[45]

While in most cases activation is dependent on TCR recognition of antigen, alternative pathways for activation have been described. For example, cytotoxic T cells have been shown to become activated when targeted by other CD8 T cells leading to tolerization of the latter.[47]

In spring 2014, the T-Cell Activation in Space (TCAS) experiment was launched to the International Space Station on the SpaceX CRS-3 mission to study how "deficiencies in the human immune system are affected by a microgravity environment".[48]

T cell activation is modulated by reactive oxygen species.[49]

A unique feature of T cells is their ability to discriminate between healthy and abnormal (e.g. infected or cancerous) cells in the body.[50] Healthy cells typically express a large number of self derived pMHC on their cell surface and although the T cell antigen receptor can interact with at least a subset of these self pMHC, the T cell generally ignores these healthy cells. However, when these very same cells contain even minute quantities of pathogen derived pMHC, T cells are able to become activated and initiate immune responses. The ability of T cells to ignore healthy cells but respond when these same cells contain pathogen (or cancer) derived pMHC is known as antigen discrimination. The molecular mechanisms that underlie this process are controversial.[50][51]

Causes of T cell deficiency include lymphocytopenia of T cells and/or defects on function of individual T cells. Complete insufficiency of T cell function can result from hereditary conditions such as severe combined immunodeficiency (SCID), Omenn syndrome, and cartilagehair hypoplasia.[52] Causes of partial insufficiencies of T cell function include acquired immune deficiency syndrome (AIDS), and hereditary conditions such as DiGeorge syndrome (DGS), chromosomal breakage syndromes (CBSs), and B-cell and T-cell combined disorders such as ataxia-telangiectasia (AT) and WiskottAldrich syndrome (WAS).[52]

The main pathogens of concern in T cell deficiencies are intracellular pathogens, including Herpes simplex virus, Mycobacterium and Listeria.[53] Also, fungal infections are also more common and severe in T cell deficiencies.[53]

Cancer of T cells is termed T-cell lymphoma, and accounts for perhaps one in ten cases of non-Hodgkin lymphoma.[54] The main forms of T cell lymphoma are:

T cell exhaustion is the progressive loss of T cell function. It can occur during sepsis and after other acute or chronic infections.[55][56]

T cell exhaustion is mediated by several inhibitory receptors including programmed cell death protein 1 (PD1), TIM3, and lymphocyte activation gene 3 protein (LAG3).[57]CD8+ T cell exhaustion occurs in some tumours, and can be partly reversed by blocking the inhibitory receptors (e.g. PD1).[58]

T cell exhaustion is associated with epigenetic changes in the T cells.[59]

( See also Immunosenescence#T cell functional dysregulation as a biomarker for immunosenescence ).

In 2015, a team of researchers led by Dr. Alexander Marson[60] at the University of California, San Francisco successfully edited the genome of human T cells using a Cas9 ribonucleoprotein delivery method.[61] This advancement has potential for applications in treating "cancer immunotherapies and cell-based therapies for HIV, primary immune deficiencies, and autoimmune diseases".[61]

Here is the original post:
T cell - Wikipedia

Read More...

Arthritis: Causes, types, and treatments – Medical News Today

June 29th, 2018 12:43 am

Welcome to Medical News Today

Healthline Media, Inc. would like to process and share personal data (e.g., mobile ad id) and data about your use of our site (e.g., content interests) with our third party partners (see a current list) using cookies and similar automatic collection tools in order to a) personalize content and/or offers on our site or other sites, b) communicate with you upon request, and/or c) for additional reasons upon notice and, when applicable, with your consent.

Healthline Media, Inc. is based in and operates this site from the United States. Any data you provide will be primarily stored and processed in the United States, pursuant to the laws of the United States, which may provide lesser privacy protections than European Economic Area countries.

By clicking accept below, you acknowledge and grant your consent for these activities unless and until you withdraw your consent using our rights request form. Learn more in our Privacy Policy.

View post:
Arthritis: Causes, types, and treatments - Medical News Today

Read More...

Comprehensive Biotechnology – 2nd Edition

June 29th, 2018 12:42 am

Editor-in-Chief

Volume Editors

Section Editors

General Preface

Nomenclature Guidelines

Permission Acknowledgments

1.01. Introduction

1.02. Amino Acid Metabolism

Glossary

1.02.1. Introduction

1.02.2. General Properties, Classification, and Structure of Amino Acids

1.02.3. Biosynthesis of Amino Acids

1.02.4. Catabolism of Amino Acids

1.02.5. Important Biomolecules Synthesized from Amino Acids

1.03. Enzyme Biocatalysis

Glossary

1.03.1. Introduction to Enzymes

1.03.2. Enzyme Kinetics

1.03.3. Enzyme Engineering

1.03.4. Enzyme Production

1.03.5. Immobilized Enzymes

1.03.6. Enzyme Applications

1.03.7. Conclusions

1.04. Immobilized Biocatalysts

1.04.1. Introduction: Definitions and Scope

1.04.2. Applications of Immobilized Enzymes

1.04.3. Methods of Enzyme Immobilization

1.04.4. Properties of Immobilized Enzymes

1.04.5. Evaluation of Enzyme Immobilization

1.04.6. Heterogeneous Biocatalysis

1.04.7. Future Prospects for Immobilized Biocatalysts

1.05. Lipids, Fatty Acids

Glossary

1.05.1. Introduction

1.05.2. Structure of Fatty Acids

1.05.3. Nomenclature

1.05.4. Form in the Cell

1.05.5. What Do Lipids Do?

1.05.6. Biosynthesis of Fatty Acids and Lipids

1.05.7. Biochemistry of Lipid Accumulation

1.06. DNA Cloning in Plasmid Vectors

Glossary

1.06.1. Introduction

1.06.2. Cloning Vectors: Replication Origins and Partition Regions

1.06.3. Cloning Vectors: Selection Markers

1.06.4. Preparing DNA Fragments for Ligation

1.06.5. Ligation Systems

1.06.6. Methods of Bacterial and Yeast Transformation

1.06.7. Exploitation of Bacteriophage Packaging for DNA Cloning in Plasmid Vectors

1.06.8. Screening of Plasmid Clones in Bacteria for the Desired Recombinant Plasmids

1.06.9. Vector-Implemented Systems for the Direct Selection of Recombinant Plasmids

1.06.10. Direct Selection of Recombinant Plasmids Involving Restriction Enzyme Digestion of the Ligation Mixture

1.06.11. Particular Features of Oligonucleotides Cloning

1.06.12. Particular Features of Cloning of PCR Amplicons

1.06.13. Introduction of Deletions into Plasmids

1.06.14. Instability of Recombinant Plasmids

1.06.15. DNA Cloning Using Site-Specific Recombination

1.06.16. DNA Cloning Using Homologous (General) Recombination

1.06.17. Employment of Transposons for In Vivo Cloning and Manipulation of Large Plasmids

1.06.18. Conclusion

1.07. Structure and Biosynthesis of Glycoprotein Carbohydrates

Glossary

Acknowledgments

1.07.1. Introduction

1.07.2. Monosaccharide Structure

1.07.3. Oligosaccharide Structure

1.07.4. Biosynthesis of Glycoproteins

1.07.5. Glycosylation of Therapeutic Glycoproteins

1.08. Nucleotide Metabolism

Glossary

1.08.1. Introduction

1.08.2. Synthesis of Phosphoribosyl Diphosphate (PRPP)

1.08.3. Purine Biosynthesis

1.08.4. Pyrimidine Biosynthesis

1.08.5. Nucleoside Triphosphate Formation

1.08.6. Deoxyribonucleotide Biosynthesis

1.08.7. Nucleotide Salvage

1.08.8. Purine and Pyrimidine Catabolism

1.08.9. Regulation of Gene Expression in Bacterial Nucleotide Synthesis

1.08.10. Exploitation of the Knowledge of Nucleotide Metabolism in Biotechnology

1.09. Organic Acids

Glossary

1.09.1. Introduction

1.09.2. Citric Acid

1.09.3. Gluconic Acid

1.09.4. Lactic Acid

1.09.5. Itaconic Acid

1.09.6. Other Acids

1.10. Peptides and Glycopeptides

Glossary

1.10.1. Introduction

1.10.2. Peptide Hormones

1.10.3. Neuropeptides

1.10.4. Antibacterial Peptides

1.10.5. Glycosylation Is a Common and Important Post-Translational Modification of Peptides

1.10.6. Common Glycosidic Linkages

1.10.7. Peptide Synthesis

1.10.8. Glycopeptide Synthesis

1.10.9. Peptides and Glycopeptides as Models of Proteins and Glycoproteins

1.10.10. Application of Synthetic Peptides and Glycopeptides for the Treatment of Disease

View post:
Comprehensive Biotechnology - 2nd Edition

Read More...

Stem Cells, Characteristics, Properties, Different …

June 27th, 2018 6:51 pm

Classification of stem cells

The Stem Cells Transplant Institute uses adult autologous mesenchymal stem cells derived from adipose tissue.

Stem cells come from two main sources; embryonic stem cells and adult stem cells. Adult stem cells do not require the destruction of an embryo and their collection and use in research is not controversial. Adult stem cells are undifferentiated totipotent or multipotent cells, found throughout the body after embryonic development.

Stem cells are also classified based on where they are collected from;allogenicstem cells are collected from the same species,xenogeneicstem cells are collected from a different species, andautologousstem cells are collected from the intended recipient.

Stem cellscan be classified by the extent to which they can differentiate into differentcelltypes. These four mainclassificationsare totipotent, pluripotent, multipotent, or unipotent. Mesenchymal stem cells, or MSCs, are multipotent stromal cellsthat can differentiate into a variety ofcelltypes, including: osteoblasts (bonecells), chondrocytes (cartilage cells), myocytes (musclecells) and adipocytes (fatcells).

The Stem Cells Transplant Institute uses adipose derived stem cells removed from either the patients abdomen or thigh and placed in a centrifuge machine that spins them very quickly, concentrating the stem cells and growth factors.

More:
Stem Cells, Characteristics, Properties, Different ...

Read More...

Parkinson’s Stem Cell Treatment | Parkinson’s Disease Story

June 27th, 2018 4:50 am

Stem Cell Therapy for Parkinsons Disease

Today, new treatments and advances in research are giving new hope to people affected by Parkinsons Disease. StemGenexStem Cell Research Centre provides Parkinsons stem cell therapy to help those with unmet clinical needs achieve optimum health and better quality of life. A clinical study registered through the National Institutes of Health (NIH) atwww.clinicaltrials.gov/stemgenex has been established to evaluate the quality of life changes in individuals with Parkinsons Disease following stem cell therapy.

Parkinsons Disease stem cell therapy is being studied for efficacy in improving the complications in patients through the use of their own stem cells.These procedures may help patients who dont respond to typical drug treatment, want to reduce their reliance on medication, or are looking to try stem cell therapy before starting drug treatment for Parkinsons.

To learn more about becoming a patient and receiving stem cell therapy through StemGenex Stem Cell Research Centre, please contact one of our Patient Advocates at (800) 609-7795. Below are some frequently asked questions aboutstem cell therapy for Parkinsons Disease.

The majority of complications in Parkinsons patients are related to the failure of dopamine neurons to do their job properly. Dopamine sends signals to the part of your brain that controls movement. It lets your muscles move smoothly and do what you want them to do. Once the nerve cells break down you no longer have enough dopamine, and you have trouble moving and completing tasks.

This stem cell treatment for Parkinson's disease is designed to target these neurons and to help with the creation of new dopamine producing neurons. In addition, stem cells may release natural chemicals called cytokines which can induce differentiation of the stem cells into dopamine producing neurons.

Upholding the highest levels of ethical conduct, safety and efficacy is our primary focus. Five clinical stem cell studies for Parkinson's Disease, Multiple Sclerosis, Osteoarthritis, Rheumatoid Arthritis and Chronic Obstructive Pulmonary Disease (COPD) are registered through the National Institutes of Health (NIH) at http://www.clinicaltrials.gov/stemgenex. Each clinical study is reviewed and approved by an independent Institutional Review Board (IRB) to ensure proper oversight and protocols are being followed.

Stem cells are the basic building blocks of human tissue and have the ability to repair, rebuild, and rejuvenate tissues in the body. When a disease or injury strikes, stem cells respond to specific signals and set about to facilitate the healing process by differentiating into specialized cells required for the bodys repair.

There are four known types of stem cells which include:

StemGenex provides autologous adult stem cells (from fat tissue) where the stem cells come from the person receiving treatment.

StemGenex provides autologous adult adipose-derived stem cells (from fat tissue) where the stem cells come from the person receiving treatment.

We tap into our bodys stem cell reserve daily to repair and replace damaged or diseased tissue. When the bodys reserve is limited and as it becomes depleted, the regenerative power of our body decreases and we succumb to disease and injury.

Three sources of stem cells from a patients body are used clinically which include adipose tissue (fat), bone marrow and peripheral blood.

Performed by Board Certified Physicians, dormant stem cells are extracted from the patients adipose tissue (fat) through a minimally invasive mini-liposuction procedure with little to no downtime.

During the liposuction procedure, a small area (typically the abdomen) is numbed with an anesthetic and patients receive mild to moderate sedation. Next, the extracted dormant stem cells are isolated from the fat and activated, and then comfortably infused back into the patient intravenously (IV) and via other directly targeted methods of administration. The out-patient procedure takes approximately four to five hours.

StemGenex provides multiple administration methods for Parkinson's Disease patients to best target the disease related conditions and symptoms which include:

Since each condition and patient are unique, there is no guarantee of what results will be achieved or how quickly they may be observed. According to patient feedback, many patients report results in one to three months, however, it may take as long as six to nine months. Individuals interested in stem cell therapy are urged to consult with their physician before choosing investigational autologous adipose-derived stem cell therapy as a treatment option.

In order to determine if you are a good candidate for adult stem cell treatment, you will need to complete a medical history form which will be provided by your StemGenex Patient Advocate. Once you complete and submit your medical history form, our medical team will review your records and determine if you are a qualified candidate for adult stem cell therapy.

StemGenex team members are here to help assist and guide you through the patient process.

Patients travel to StemGenex located in Del Mar, California located in San Diego County for stem cell treatment from all over the United States, Canada and around the globe. Treatment will consist of one visit lasting a total of three days. The therapy is minimally invasive and there is little to no down time. Majority of patients fly home the day after treatment.

We provide stem cell therapy for a wide variety of diseases and conditions for which traditional treatment offers less than optimal options. Some conditions include Multiple Sclerosis, Parkinson's Disease, Rheumatoid Arthritis, Osteoarthritis and Chronic Obstructive Pulmonary Disease (COPD).

The side effects of the mini-liposuction procedure are minimal and may include but are not limited to: minor swelling, bruising and redness at the procedure site, minor fever, headache, or nausea. However, these side effects typically last no longer than 24 hours and are experienced mostly by people with sensitivity to mild anesthesia. No long-term negative side effects or risks have been reported.

The side effects of adipose-derived stem cell therapy are minimal and may include but are not limited to: infection, minor bleeding at the treatment sites and localized pain. However, these side effects typically last no longer than 24 hours. No long-term negative side effects or risks have been reported.

StemGenex provides adult stem cell treatment with mesenchymal stem cells which come from the person receiving treatment. Embryonic stem cells are typically associated with ethical and political controversies.

The FDA is currently in the process of defining a regulatory path for cellular therapies. A Scientific Workshop and Public Hearing Draft Guidances Relating to the Regulation of Human Cells, Tissues or Cellular or Tissue-Based Products was held in September 2016 at the National Institutes of Health (NIH) in Bethesda, MD. Currently, stem cell treatment is not FDA approved.

In March 2016, bipartisan legislation, the REGROW Act was introduced to the Senate and House of Representatives to develop and advance stem cell therapies.

Stem cell treatment is not covered by health insurance at this time. The cost for standard preoperative labs are included. Additional specific labs may be requested at the patients expense.

People suffering from Parkinson's Disease often suffer from the following complications::

Link:
Parkinson's Stem Cell Treatment | Parkinson's Disease Story

Read More...

Gregor Mendel – Wikipedia

June 27th, 2018 4:49 am

Gregor Johann Mendel (Czech: eho Jan Mendel;[1] 20 July 1822[2] 6 January 1884) (English: ) was a scientist, Augustinian friar and abbot of St. Thomas' Abbey in Brno, Margraviate of Moravia. Mendel was born in a German-speaking family[3] in the Silesian part of the Austrian Empire (today's Czech Republic) and gained posthumous recognition as the founder of the modern science of genetics. Though farmers had known for millennia that crossbreeding of animals and plants could favor certain desirable traits, Mendel's pea plant experiments conducted between 1856 and 1863 established many of the rules of heredity, now referred to as the laws of Mendelian inheritance.[4]

Mendel worked with seven characteristics of pea plants: plant height, pod shape and color, seed shape and color, and flower position and color. Taking seed color as an example, Mendel showed that when a true-breeding yellow pea and a true-breeding green pea were cross-bred their offspring always produced yellow seeds. However, in the next generation, the green peas reappeared at a ratio of 1 green to 3 yellow. To explain this phenomenon, Mendel coined the terms recessive and dominant in reference to certain traits. (In the preceding example, the green trait, which seems to have vanished in the first filial generation, is recessive and the yellow is dominant.) He published his work in 1866, demonstrating the actions of invisible factorsnow called genesin predictably determining the traits of an organism.

The profound significance of Mendel's work was not recognized until the turn of the 20th century (more than three decades later) with the rediscovery of his laws.[5] Erich von Tschermak, Hugo de Vries, Carl Correns and William Jasper Spillman independently verified several of Mendel's experimental findings, ushering in the modern age of genetics.[4]

Mendel was born into a German-speaking family in Hynice (Heinzendorf bei Odrau in German), at the Moravian-Silesian border, Austrian Empire (now a part of the Czech Republic).[3] He was the son of Anton and Rosine (Schwirtlich) Mendel and had one older sister, Veronika, and one younger, Theresia. They lived and worked on a farm which had been owned by the Mendel family for at least 130 years.[6] During his childhood, Mendel worked as a gardener and studied beekeeping. As a young man, he attended gymnasium in Opava (called Troppau in German). He had to take four months off during his gymnasium studies due to illness. From 1840 to 1843, he studied practical and theoretical philosophy and physics at the Philosophical Institute of the University of Olomouc, taking another year off because of illness. He also struggled financially to pay for his studies, and Theresia gave him her dowry. Later he helped support her three sons, two of whom became doctors.

He became a friar in part because it enabled him to obtain an education without having to pay for it himself. As the son of a struggling farmer, the monastic life, in his words, spared him the "perpetual anxiety about a means of livelihood."[8] He was given the name Gregor (eho in Czech)[1] when he joined the Augustinian friars.

When Mendel entered the Faculty of Philosophy, the Department of Natural History and Agriculture was headed by Johann Karl Nestler who conducted extensive research of hereditary traits of plants and animals, especially sheep. Upon recommendation of his physics teacher Friedrich Franz,[10] Mendel entered the Augustinian St Thomas's Abbey in Brno (called Brnn in German) and began his training as a priest. Born Johann Mendel, he took the name Gregor upon entering religious life. Mendel worked as a substitute high school teacher. In 1850, he failed the oral part, the last of three parts, of his exams to become a certified high school teacher. In 1851, he was sent to the University of Vienna to study under the sponsorship of Abbot C. F. Napp so that he could get more formal education. At Vienna, his professor of physics was Christian Doppler.[12] Mendel returned to his abbey in 1853 as a teacher, principally of physics. In 1856, he took the exam to become a certified teacher and again failed the oral part. In 1867, he replaced Napp as abbot of the monastery.[13]

After he was elevated as abbot in 1868, his scientific work largely ended, as Mendel became overburdened with administrative responsibilities, especially a dispute with the civil government over its attempt to impose special taxes on religious institutions.[14] Mendel died on 6 January 1884, at the age of 61, in Brno, Moravia, Austria-Hungary (now Czech Republic), from chronic nephritis. Czech composer Leo Janek played the organ at his funeral. After his death, the succeeding abbot burned all papers in Mendel's collection, to mark an end to the disputes over taxation.[15]

Gregor Mendel, who is known as the "father of modern genetics", was inspired by both his professors at the Palack University, Olomouc (Friedrich Franz and Johann Karl Nestler), and his colleagues at the monastery (such as Franz Diebl) to study variation in plants. In 1854, Napp authorized Mendel to carry out a study in the monastery's 2 hectares (4.9 acres) experimental garden,[16] which was originally planted by Napp in 1830.[13] Unlike Nestler, who studied hereditary traits in sheep, Mendel used the common edible pea and started his experiments in 1856.

After initial experiments with pea plants, Mendel settled on studying seven traits that seemed to be inherited independently of other traits: seed shape, flower color, seed coat tint, pod shape, unripe pod color, flower location, and plant height. He first focused on seed shape, which was either angular or round. Between 1856 and 1863 Mendel cultivated and tested some 28,000 plants, the majority of which were pea plants (Pisum sativum).[18][19][20] This study showed that, when true-breeding different varieties were crossed to each other (e.g., tall plants fertilized by short plants), in the second generation, one in four pea plants had purebred recessive traits, two out of four were hybrids, and one out of four were purebred dominant. His experiments led him to make two generalizations, the Law of Segregation and the Law of Independent Assortment, which later came to be known as Mendel's Laws of Inheritance.[21]

Mendel presented his paper, "Versuche ber Pflanzenhybriden" ("Experiments on Plant Hybridization"), at two meetings of the Natural History Society of Brno in Moravia on 8 February and 8 March 1865. It generated a few favorable reports in local newspapers,[23] but was ignored by the scientific community. When Mendel's paper was published in 1866 in Verhandlungen des naturforschenden Vereines in Brnn,[24] it was seen as essentially about hybridization rather than inheritance, had little impact, and was only cited about three times over the next thirty-five years. His paper was criticized at the time, but is now considered a seminal work.[25] Notably, Charles Darwin was unaware of Mendel's paper, and it is envisaged that if he had, genetics as we know it now might have taken hold much earlier.[26][27] Mendel's scientific biography thus provides an example of the failure of obscure, highly original, innovators to receive the attention they deserve.[28]

Mendel began his studies on heredity using mice. He was at St. Thomas's Abbey but his bishop did not like one of his friars studying animal sex, so Mendel switched to plants. Mendel also bred bees in a bee house that was built for him, using bee hives that he designed.[30] He also studied astronomy and meteorology,[13] founding the 'Austrian Meteorological Society' in 1865.[12] The majority of his published works was related to meteorology.[12]

Mendel also experimented with hawkweed (Hieracium)[31] and honeybees. He published a report on his work with hawkweed,[32] a group of plants of great interest to scientists at the time because of their diversity. However, the results of Mendel's inheritance study in hawkweeds was unlike his results for peas; the first generation was very variable and many of their offspring were identical to the maternal parent. In his correspondence with Carl Ngeli he discussed his results but was unable to explain them.[31] It was not appreciated until the end of the nineteen century that many hawkweed species were apomictic, producing most of their seeds through an asexual process.

None of his results on bees survived, except for a passing mention in the reports of Moravian Apiculture Society.[33] All that is known definitely is that he used Cyprian and Carniolan bees,[34] which were particularly aggressive to the annoyance of other monks and visitors of the monastery such that he was asked to get rid of them.[35] Mendel, on the other hand, was fond of his bees, and referred to them as "my dearest little animals".[36]

He also described novel plant species, and these are denoted with the botanical author abbreviation "Mendel".[37]

It would appear that the forty odd scientists who listened to Mendel's two path-breaking lectures failed to understand his work. Later, he also carried a correspondence with Carl Naegeli, one of the leading biologists of the time, but Naegli too failed to appreciate Mendel's discoveries. At times, Mendel must have entertained doubts about his work, but not always: "My time will come," he reportedly told a friend.[8]

During Mendel's lifetime, most biologists held the idea that all characteristics were passed to the next generation through blending inheritance, in which the traits from each parent are averaged. Instances of this phenomenon are now explained by the action of multiple genes with quantitative effects. Charles Darwin tried unsuccessfully to explain inheritance through a theory of pangenesis. It was not until the early twentieth century that the importance of Mendel's ideas was realized.

By 1900, research aimed at finding a successful theory of discontinuous inheritance rather than blending inheritance led to independent duplication of his work by Hugo de Vries and Carl Correns, and the rediscovery of Mendel's writings and laws. Both acknowledged Mendel's priority, and it is thought probable that de Vries did not understand the results he had found until after reading Mendel.[5] Though Erich von Tschermak was originally also credited with rediscovery, this is no longer accepted because he did not understand Mendel's laws.[38] Though de Vries later lost interest in Mendelism, other biologists started to establish modern genetics as a science.[5] All three of these researchers, each from a different country, published their rediscovery of Mendel's work within a two-month span in the Spring of 1900.

Mendel's results were quickly replicated, and genetic linkage quickly worked out. Biologists flocked to the theory; even though it was not yet applicable to many phenomena, it sought to give a genotypic understanding of heredity which they felt was lacking in previous studies of heredity which focused on phenotypic approaches.[40] Most prominent of these previous approaches was the biometric school of Karl Pearson and W. F. R. Weldon, which was based heavily on statistical studies of phenotype variation. The strongest opposition to this school came from William Bateson, who perhaps did the most in the early days of publicising the benefits of Mendel's theory (the word "genetics", and much of the discipline's other terminology, originated with Bateson). This debate between the biometricians and the Mendelians was extremely vigorous in the first two decades of the twentieth century, with the biometricians claiming statistical and mathematical rigor,[41] whereas the Mendelians claimed a better understanding of biology.[42][43] (Modern genetics shows that Mendelian heredity is in fact an inherently biological process, though not all genes of Mendel's experiments are yet understood.)[44][45]

In the end, the two approaches were combined, especially by work conducted by R. A. Fisher as early as 1918. The combination, in the 1930s and 1940s, of Mendelian genetics with Darwin's theory of natural selection resulted in the modern synthesis of evolutionary biology.[46][47]

In 1936, R.A. Fisher, a prominent statistician and population geneticist, reconstructed Mendel's experiments, analyzed results from the F2 (second filial) generation and found the ratio of dominant to recessive phenotypes (e.g. green versus yellow peas; round versus wrinkled peas) to be implausibly and consistently too close to the expected ratio of 3 to 1.[48][49][50] Fisher asserted that "the data of most, if not all, of the experiments have been falsified so as to agree closely with Mendel's expectations,"[48] Mendel's alleged observations, according to Fisher, were "abominable", "shocking",[51] and "cooked".[52]

Other scholars agree with Fisher that Mendel's various observations come uncomfortably close to Mendel's expectations. Dr. Edwards,[53] for instance, remarks: "One can applaud the lucky gambler; but when he is lucky again tomorrow, and the next day, and the following day, one is entitled to become a little suspicious". Three other lines of evidence likewise lend support to the assertion that Mendels results are indeed too good to be true.[54]

Fisher's analysis gave rise to the Mendelian Paradox, a paradox that remains unsolved to this very day. Thus, on the one hand, Mendel's reported data are, statistically speaking, too good to be true; on the other, "everything we know about Mendel suggests that he was unlikely to engage in either deliberate fraud or in unconscious adjustment of his observations."[54] A number of writers have attempted to resolve this paradox.

One attempted explanation invokes confirmation bias.[55] Fisher accused Mendel's experiments as "biased strongly in the direction of agreement with expectation... to give the theory the benefit of doubt".[48] This might arise if he detected an approximate 3 to 1 ratio early in his experiments with a small sample size, and, in cases where the ratio appeared to deviate slightly from this, continued collecting more data until the results conformed more nearly to an exact ratio.

In his 2004, J.W. Porteous concluded that Mendel's observations were indeed implausible.[56] However, reproduction of the experiments has demonstrated that there is no real bias towards Mendel's data.[57]

Another attempt[54] to resolve the Mendelian Paradox notes that a conflict may sometimes arise between the moral imperative of a bias-free recounting of one's factual observations and the even more important imperative of advancing scientific knowledge. Mendel might have felt compelled to simplify his data in order to meet real, or feared, editorial objections.[53] Such an action could be justified on moral grounds (and hence provide a resolution to the Mendelian Paradox), since the alternativerefusing to complymight have retarded the growth of scientific knowledge. Similarly, like so many other obscure innovators of science,[53][28] Mendel, a little known innovator of working-class background, had to break through the cognitive paradigms and social prejudices of his audience.[53] If such a breakthrough could be best achieved by deliberately omitting some observations from his report and adjusting others to make them more palatable to his audience, such actions could be justified on moral grounds.[54]

Daniel L. Hartl and Daniel J. Fairbanks reject outright Fisher's statistical argument, suggesting that Fisher incorrectly interpreted Mendel's experiments. They find it likely that Mendel scored more than 10 progeny, and that the results matched the expectation. They conclude: "Fisher's allegation of deliberate falsification can finally be put to rest, because on closer analysis it has proved to be unsupported by convincing evidence."[51][58] In 2008 Hartl and Fairbanks (with Allan Franklin and AWF Edwards) wrote a comprehensive book in which they concluded that there were no reasons to assert Mendel fabricated his results, nor that Fisher deliberately tried to diminish Mendel's legacy.[59] Reassessment of Fisher's statistical analysis, according to these authors, also disprove the notion of confirmation bias in Mendel's results.[60][61]

More here:
Gregor Mendel - Wikipedia

Read More...

Stem Cell Clinics: The Future of Medical Tourism in Costa …

June 27th, 2018 4:47 am

(PRWEB) MARCH 18, 2016 Bioscience Americas, LLC (http://www.bioscienceamericas.com), a leading international developer of autologous stem cell therapy centers for the treatment of autoimmune diseases, is pleased to announce that its lead scientific researcher, Dr. Anand Srivastava, has been invited to speak at the Fifth Annual European Biosimilar Conference to be held in Valencia, Spain, June 27-29, 2016.

Dr. Srivastava will speak on the dynamic world of stem cell research and the progress being made by Bioscience Americas research partner, the Global Institute of Stem Cell Therapy and Research. The Global Institute is the leader in the field of adult stem cell research and has devoted the last fifteen years and more than $400 million in creating treatments for many of the worlds most devastating diseases. Dr. Srivastava is recognized as being a pioneer in the field and is among its leaders.

Euro Biosimilars 2016 is a three-day event that brings together more than 300 top scientists and researchers in the biologic sector. Representatives from research organizations, top universities, and biopharmaceutical companies will be in attendance. The goal of the conference is to bring together the preeminent minds in the field to foster learning and research.

In commenting on the invitation, Bioscience Americas CEO Eric Stoffers said, Dr. Srivastavas participation is a feather in our cap. We are pleased to be associated with him and the Global Institute team.

In other news, Bioscience Americas has been granted an exclusive license from the Global Institute to develop adult stem cell treatment centers in Central America including Costa Rica. Costa Rica is well known as a major medical tourism destination for patients from North America and Europe. Bioscience Americas President Bill Deegan said that the company has initiated discussions with medical institutions in Costa Rica with the expectation of creating recognized treatment affiliations.

Bioscience Americas currently has under development a stem cell clinic in Rio Negro, Colombia, to be affiliated with San Vicente Hospital, South Americas leading organ transplant hospital.

In addition to its expansion into Central America, Bioscience Americas has an exclusive to develop medical stem cell facilities throughout South America to treat local patients as well as patients obtained through its medical tourism efforts.

The Global Institute of Stem Cell Therapy and Research is a consortium of research scientists from throughout the world. It is based at the University of California Medical Center in San Diego.

Bioscience Americas is the joint venture partner of the Global Institute. Its mission is to bring the therapies created in the lab to the marketplace. Bioscience Americas is based in Phoenix, Arizona

See also http://stemcellstransplantinstitute.com

Source

Read the original here:
Stem Cell Clinics: The Future of Medical Tourism in Costa ...

Read More...

Stem Cell Treatment: Costa Rica vs Panama

June 27th, 2018 4:47 am

We have received several inquiries about the stem cell clinic that was previously in Costa Rica, but moved to Panama, and is now known as the Stem Cell Institute of Panama.People were curious about the circumstances surrounding their move, and how the stem cell treatment at our clinic differ in terms of procedures, price, and efficacy?

Why did Stem Cell Institute Panama move? Is the health care system better in Panama? What Happened?

First, it is important to mention that when the Stem Cell Institute of Panama moved from Costa Rica to Panama, stem cell treatment laws were being modified in Costa Rica and stem cell treatments were not legally approved by the Costa Rican Government at that time, a situation that has changed today.

In 2010, Ileana Herrera, the head of the health ministrys research council in Costa Rica, said the Stem Cell Institute of Panama, which opened in Costa Rica in 2006, would be allowed to store adult stem cells extracted from patients own fat tissue, bone marrow and donated umbilical cords, but not perform treatments since efficiency and safety were uncertain.

Today stem cell treatments in Costa Rica are legally approved and promoted by relevant medical clinics like the Stem Cells Transplant Institute in Escaz. Regulations in Costa Rica were modified recently in favor of the use of stem cells. The complaints by Stem Cell Institute of Panama originated due to the situation in Costa Rica at that specific time. Research into the type of comments and complaints in searches related to the Panamanian company would reveal inquiries such as:

Many articles have been written in response to the above questions by various sources with statements both pro and con, but those comments, and / or complaints would be made about any clinic anywhere because of the controversy surrounding these new stem cell treatments.

The Stem Cell Transplants Institute in Panama, as well as the healthcare system, faces many challenges today that interfere with complete development.

Despite advances in stem cells transplants in Panama and in Panamas health care in the past few years, there is a shortage of healthcare professionals. This is not an issue limited to the health sector, but rather a tendency that affects multiple fields of the economy in Panama. Also, although the country has made important advances toward universal healthcare coverage, according to the Pan American Health Organization, public and private sector covered around 90% of the population in 2014, access to health services is not equally available for everyone. There is a marked discrepancy between health outcomes in urban and rural settings.

In comparison, the Costa Rican healthcare system is rated very highly on an international level, and the countrys citizens enjoy the health and life expectancy equal to that of more developed nations. Nearly the entire population of Costa Rica had healthcare coverage by the year 2006. In addition, the country ranks among one of the best for specialized medical professionals. This is the case with Dr. Leslie Mesn, who specializes in stem cells treatments and anti-aging therapies in Escaz.Get more information here.

To summarize, the healthcare in Costa Rica has many advantages when compared to Panama. Additional benefits include, security and weather. For example, Panama is more hot, humid, and cloudy and has a prolonged rainy season. Costa Rica is a great destination for stem cell therapy.

How do our treatments differ? Are Stem Cells Institute Panama cures and methods different from ours?

The Stem Cell Institute of Panama utilizes mainly combinations of allogeneic human umbilical cord stem cells and autologous bone marrow stem cells to treat the diseases. The Stem Cells Institute in Costa Rica uses adult autologous stem cells obtained from the patients own fatty tissue.

Allogeneic stem cell transplantation utilized by Stem Cell Institute of Panama is a procedure in which a person receives stem cells from a genetically similar, but not identical, donor. These types of cells are more vulnerable to rejection than autologous cells (cells derived from the same individual). In comparison, the Stem Cells Transplant Institute in Costa Rica uses exclusively adult autologous stem cells obtained from the patients own tissue, so risk of rejections is almost non-existent. Adult stem cells are less likely to be rejected when used in transplants and they are possible to reprogram. The success of using adult stem cells has been demonstrated in various clinical applications. Top stem cell research universities have studies suggesting that adult stem cells may have greater plasticity than was originally thought, which means that they may be able to differentiate into a greater range of specialized cell types. At present, however, it would appear that embryonic stem cells still have the advantage in their ability to differentiate more readily than adult stem cells, but as we just mentioned, the possibility of rejection is also much higher.

Another important difference between the Stem Cell Institute of Panama treatments and the treatments at the Stem Cells Transplant Institute of Costa Rica is that since adult stem cells are derived from adult tissues and, of course, with consent from the patient, there is little if any ethical dilemma to adult stem cell therapies. Embryonic stem cells and umbilical cord stem cells, on the other hand, have triggered enormous debate due to the destruction of an embryo following cell extraction or issues surrounding the collection and application of stem cells from the umbilical cord.

At the Stem Cells Transplant Institute in Costa Rica, we use adult stem cells. We harvest stem cells from a sample of your own bone marrow or adipose tissue and later inject them intravenously or directly in the zone required. The therapies are legally approved in Costa Rica and are highly controlled. You can be assured that we follow the highest ethical standards and do not practice any procedures that may be viewed as crossing the ethical standards of human life.

Are therapies more expensive in Costa Rica? Are Stem Cell Institute Panama costs lower?

No, the cost of treatment at the Stem Cell Institute of Panama is very similar to Costa Rica. The experts at the Stem Cells Institute in Costa Rica use state-of-the-art technology and provide high quality care at a reasonable price.

Do treatments in Costa Rica differ from the treatments at the Stem Cell Institute of Panama in terms of efficacy?

Stem cell transplants in Panama and Costa Rica are being used for autism, COPD, anti-aging and many other degenerative and inflammatory diseases. People with various illnesses interested in stem cell treatment at the Stem Cell Institute of Panama, have done an internet search for:

It should be noted that the Stem Cells Transplant Institute of Costa Rica offers the same treatments, and more in our new, ultra-modern clinic in the CIMA Medical Center. In terms of efficacy, stem cells by themselves have the remarkable potential to develop into many different cell types in the body independently of the health center; however, it requires a strict isolation process and qualified expertise for the correct application.

At the Stem Cells Transplant Institute in Costa Rica, we guarantee you we strictly follow well-designed isolation protocols, with high standards of quality, hygiene, and top technological resources. The therapies are applied by highly qualified professionals so you receive the best possible results. The procedures followed by Stem Cell Transplant Institute of Panama are not known to us.

The Stem Cell Institute of Panama moved from Costa Rica because of temporary circumstances that have been resolved and have nothing to do with aspects of efficacy, lower costs or lack of resources in Costa Rica. In comparison, Costa Rica has a higher standard of healthcare and expert institutions like the Stem Cells Transplant Institute that offer legally approved and high-quality therapies.

Read the original post:
Stem Cell Treatment: Costa Rica vs Panama

Read More...

Ethical and legal issues and the "new genetics" | The …

June 27th, 2018 4:47 am

In recent years there has been an explosion of knowledge in the science of genetics but often less general awareness of the ethical and legal implications of genetic advances. Fueled by sensationalist media reporting, developments are often exaggerated and create unrealistic expectations for the "new genetics".1 Medicine has a great capacity to test and screen for gene mutations, but currently little ability to cure the clinical consequences of these mutations. Because of the newness of this information, and the deterministic way in which many interpret the data, there is a risk that predictive genetic information will be misunderstood and too much weight will be placed on it.1 Genetic determinism is particularly unwelcome, because most common diseases involve the interaction of predisposing genes with a facilitative environment the value of genetic knowledge is usually to allow accurate environmental or pharmacological intervention.

Concerns have been raised about the misuse of genetic information, particularly with computerisation and linkage of health records.2 These concerns may reduce the willingness of individuals to undergo genetic testing, even when the tests are clearly beneficial. In a recent initiative in Victoria, only a small proportion of people offered free gene screening for haemochromatosis accepted the test. One can only speculate as to the reasons for this low uptake, but fears about confidentiality and potential misuse of the information may have played some part.3,4 This was in spite of the fact that the clinical consequences of haemochromatosis can be completely averted if appropriate action is taken. Furthermore, a unique agreement had been reached with the Investment Financial Services Association (IFSA), the peak body of the life insurance industry in Australia, that people who tested positive for haemochromatosis and agreed to take preventive measures (regular blood donation) would not be refused life insurance or have their premiums loaded because of their genetic status.5

In many cases, ethical concerns about genetics simply underscore existing concerns about marginalisation, stigmatisation and discrimination of disadvantaged groups. Although these concerns may be valid, they are not new or unique to genetics. However, the sheer scope of genetics and the complex nature of genetic information, extending beyond individuals, mean that these concerns are now more pressing. There are also some significant new ethical and legal issues emerging from the application of the human genome project to medicine, particularly with regard to predictive information about common diseases and for traits (such as criminality or ability) that are not diseases at all.

Our aim in this article is to give a broad overview of the main ethical and legal challenges presented by the new genetics and their implications for the medical profession. In many instances, these issues have not been resolved and the full debate remains to be had. Typically, there are no easy answers to the dilemmas raised, but awareness of what the key issues are and sketching of directions will help healthcare professionals understand and participate in these developments.

Some basic principles to keep in mind when considering ethics are presented in Box 1. In Australia, ethics usually revolves around informed choices by individuals. However, the pervasive and predictive nature of genetic information means that every clinician has to be familiar not only with its clinical significance, but also the ethical implications.7 As well as thinking of patients as individuals, doctors must think of families, because gene analyses affect parents, siblings, children, the unborn, and sometimes entire ethnic groups. Doctors must be aware that this responsibility to family may conflict with the individual's right to privacy.

There are some fairly straightforward ethical issues that arise with respect to genetics:

Is the application of genetics lawful? If it is not, it cannot be offered, as is the case for using DNA to select the sex of an embryo in Victoria, except to avoid transmission of a genetic disorder.8 Even if it is lawful, do you, as a doctor have an ethical objection to this test or procedure, such that you would have to advise the patient to see another doctor?

Is it safe? If it can cause harm, is the likely harm balanced by the likely benefit?

Is it helpful in dealing with the problems you perceive as relevant to this patient, this family? Is it helpful in dealing with the problems as perceived by them?

Is it evidence-based, or still a research procedure?

Is it cost-effective?

These types of issues arise with every medical procedure, but arise with an unprecedented intensity for genetics.

The availability of genetic testing offers the "capacity to know" about one's genetic destiny with greater certainty than revealed by family history alone, but knowledge will not always be welcome and individuals are generally at liberty to decide whether they want this information. The ethics of testing are different if action can be taken to prevent or treat a disease, as for haemochromatosis, as compared with conditions for which no treatments are presently available, such as Huntington disease. If prevention or early treatment is available, it is unethical not to offer testing. However, some people want and use knowledge even if there is no treatment, for example, for reproductive choice. Particular care needs to be taken with the predictive genetic testing of children: this is widely regarded as inappropriate unless preventive strategies are available.9,10

The capacity to use test data for reproductive choice brings a range of ethical dilemmas. Genetic testing of fetuses with a view to termination of pregnancy is met with alarm by some disability advocates, who are concerned about approaches that treat disability as a "problem" that should be prevented using genetic means, rather than dealing with the issue of non-discrimination of people with disabilities.11 Concerns have been expressed that the range of conditions that may be tested for will extend to good looks and abilities, leading to fears of "designer babies" and the spectre of eugenics.

Society will set the limits within which choices will be made. Although there is some disquiet about genetic interventions, as a society we need to ensure that we have a balanced ethical debate on issues of concern and that we distil the real ethical issues. The challenge ahead is to ensure that the newness of genetics does not unreasonably impede its implementation. There may be a natural resistance to the expansion of genetic science and technology, particularly where it extends beyond the therapeutic model (eg, to enhance appearance or intelligence), but it is important that we not limit the available options unless there is sound justification for doing so. This also underscores the importance of offering appropriate genetic counselling, particularly for the more complex situations in predictive or prenatal testing, so that individuals can make informed choices in both an individual and a social context.

The law needs to set limits within which scientific development and clinical practice can operate. Although the scope and extent of protection that should be provided by the law is a matter for debate, there is consensus that the law should protect individuals from avoidable harm.

The metaphor of the law "limping in the rear" of the march of science12 is often invoked, and nowhere more so than in the context of the new genetics. There are few laws in Australia regulating the collection and use of personal genetic information, and none that do so explicitly for genetic information. The present legal framework in this area consists primarily of anti-discrimination and privacy legislation. We end up with a complex legislative patchwork, which has some influence on the permissible collection and use of personal human genetic information, but does not effectively "regulate" it. For this reason, there has been much agitation for reform to respond to the new challenges created by the increase in the range of available genetic testing.

The collection and use of human genetic information, and the measures that may be necessary to protect the individual are under intense scrutiny by the Australian Law Reform Commission (ALRC) and the Australian Health Ethics Committee (AHEC).13 A discussion paper released in August 2002 canvasses a range of issues and makes numerous proposals for regulation.14 These are being finalised for public discussion and possible enactment.

The availability of the new genetics has implications with regard to doctors' legal duty of care to their patients. Doctors have a responsibility to keep up to date with the new genetics so that they can give advice on what tests are available. As with any medical procedure, the law protects the autonomy of competent individuals to decide whether to undergo genetic testing and to accept medical treatment or advice about lifestyle changes arising from such testing. However, there are tensions between the rights of individuals and the rights of the family, for whom this information may have relevance to health. Privacy regulation in Australia comprises a combination of common law and legislation.15 At present, no special status is afforded to genetic information. Strictly, even taking a person's family history involves a potential breach of the privacy of other family members. This difficulty has now been addressed through the Federal Privacy Commissioner making a Public Interest Determination to cover family medical histories.16

Problems can also arise with the disclosure of an individual's genetic information to other family members. At present, standard rules regarding the disclosure of health information apply, limiting disclosure to circumstances where there is a threat of serious and imminent harm to others or a serious public health risk.17 However, the familial nature of genetic information demands some modification of the usual principles of privacy and non-disclosure, in both directions. The information should be able to be shared with family members whose health may benefit from access to this information by alerting them to the risk of genetic disease and enabling them to institute preventive or therapeutic strategies,18 but be protected more carefully from outsiders. One aspect of the ALRC/AHEC proposals that is likely to be of practical relevance to doctors is the proposal to expand the circumstances in which genetic information may be released to other family members.14

There are also vexing questions about whether third parties should be entitled to access personal genetic information. When applying for insurance, individuals are required to disclose family history and the results of any genetic tests,19 and insurers are entitled to take this information into account for the purposes of underwriting for life insurance and related products. Insurers are exempt from disability discrimination,20 but must be able to justify the way in which they use the genetic information with regard to actuarial, statistical or other data. There are concerns about the adequacy of available data for underwriting purposes and the potential for unfair genetic discrimination (Box 2).22 In several jurisdictions, including the United Kingdom, moratoriums have been introduced on the use of genetic test information by insurers, or such use has been prohibited by legislation. Current proposals for reform put forward by the ALRC/AHEC retain the insurers' entitlement to use genetic test information for risk assessment, but seek to regulate more stringently what genetic tests can be used by devolving this responsibility to the proposed Human Genetics Commission of Australia.14

In the sphere of employment, the challenge is to ensure that legitimate uses of genetic test information are permitted, such as offering screening for susceptibility to workplace hazards that cannot otherwise be avoided, but to protect employees and job seekers from unfair discrimination motivated by employers' expediency and profit. The proposals advanced by the ALRC/AHEC seek to strike a proper balance to allow uses of genetic testing which are consistent with occupational health and safety interests, but prohibit other uses.14

Fundamental questions are also being raised about the status of genetic samples collected for pathology examination, such as blood or other sources of DNA, including pathological tissue blocks and human tissue on microscope slides. At present, these are generally regarded as the property of the hospital, over which the donor may have no legally enforceable rights. Although such samples have no clear legal status as property, opinions are divided over whether it is appropriate to create legally enforceable rights, especially if the sample proves to have a commercial value.23,24 The line between research and clinical care is ethically blurred when a sample is studied by a specialist or a pathologist, and becomes even more confusing as we move towards an increasingly commercialised environment in which the potential for profit from genetic knowledge is real and the clamour for patents resonates.25

When it comes to regulation of artificial reproductive technology, the situation is even more confused. In Victoria, South Australia and Western Australia, there is legislation regulating this area.26-28 These Acts, to varying degrees, restrict the circumstances in which genetic testing can be undertaken. The other States and Territories have no legislation, and this lack of uniformity invites "doctor shopping".29

There is great concern that genetics will be used for "designer babies", but no one knows whether this will be possible, economically viable, or wanted by anyone. Couples are now being allowed to choose pregnancies that will provide an infant with a particular genetic make-up in the context of a sibling with a very serious illness.30 The baby can then be a donor of cord blood stem cells to the seriously ill sibling. Although this is occasionally described as "designer babies", it is clearly far from what concerns the public. It is important for doctors to be aware of and emphasise the difference between the use of clinical interventions to save the lives of children with serious diseases, as compared with the use of procedures for trivial purposes such as choosing hair or eye colour. The former is generally thought to be ethical, the latter unethical. There is concern that over-the-counter DNA tests will soon be available, but knowledge has for generations been regarded as a positive, not a negative, commodity. Doctors may be the gatekeepers of the new genetic knowledge, but they will not be its owners.

The draft sequence of the human genome is now on the Web, and advances in our understanding of the relationships between genes and environment and disease occur almost daily. Challenging issues lie on the horizon in terms of defining the role of doctors with respect to their patients and the extent of their duty of care, as we learn more of the relationship between genes, the environment and complex diseases and behaviours. Because of community concerns, there will be pressure for laws to regulate the application of genetics in medicine. However, knowledge of genetics and the methods of applying it to people are changing rapidly, so there is an overwhelming need for flexibility in the development of solutions. This may encourage the use of regulations and other "soft" laws, such as guidelines and codes of practice, in preference to statute law, as the former are easier to adapt to new situations.

The new genetics has enormous potential to confer clinical benefits. The challenge is to harness these benefits and to minimise the risk of harm. Fortunately, most doctors, patients and families want to make sensible choices. The ethical interpretations we offer, and the legal framework that is used to interpret these ethical principles, must ensure that application of the new genetics is not unreasonably restricted as it develops. The better informed doctors are of the ethical and legal issues arising from the new genetics, the better equipped they will be to give appropriate information to patients and the community.

1: Ethical principles

There are many religions and belief systems, and it is important that healthcare ethics should be able to inform decisions of the whole community. Four principles that could underpin an ethical approach to healthcare issues are: 6

1. Respect autonomy: educate, communicate, consult, respect and empower. (Autonomy is both very important and controversial in genetics. Conflict between the rights of the individual, the family and the community arise more often for genetic issues than for most medical procedures.)

2. Beneficence: provide net benefits, but ensure these are realistic.

3. Non-maleficence: do no avoidable harm, to individuals or groups.

4. Promote justice: fair distribution of resources, respect for rights and respect for morally acceptable laws. (One problem of genetics is that it "is not fair". We are not "created equal", because our genetics differs, and with it our health risks. However, the doctor has to try to create a level playing field, in the interests of justice.)

When applied in the context of genetics, beneficence and non-maleficence sit easily, but, for the reasons noted above, autonomy and justice are problematic.

2: Genetic discrimination

Genetic discrimination can be defined as different treatment of an individual by a third party such as an insurer or employer on the basis of genetic factors real, inferred or wrongly imputed. Discrimination can be positive or negative: the concerns relate to unfavourable discrimination, involving decisions adverse to the interests of the individuals involved. Unfavourable discrimination can be justifiable and lawful: anti-discrimination legislation, which provides protection for some forms of unfair discrimination, contains exemptions from discrimination by insurers and employers in some circumstances.

A team of researchers, funded by the Australian Research Council, is conducting a major empirical study into the nature and extent of genetic discrimination in Australia and its social and legal implications.21 The study seeks to gain the experience and perspective of all key stakeholders: "consumers" (those considered to be at risk because of a genetic test result or their family history); third parties such as insurers and employers (the groups against which allegations of genetic discrimination have most frequently been made); and the various organisations within the legal system through which complaints of alleged genetic discrimination may be pursued.

Read more:
Ethical and legal issues and the "new genetics" | The ...

Read More...

NJVMA | New Jersey Veterinary Medical Association

June 26th, 2018 8:46 am

The New Jersey Veterinary Medical Association (NJVMA) Animal Hall of Fame Committee has selected two dogs, one rabbit, one horse and an animal sanctuary for induction into the 23rd Annual NJVMA Animal Hall of Fame.

The NJVMA is honored to recognize the animals and people that inspired us to share their stories and to recognize the role that veterinarians play in strengthening the human-animal bond, said Dr. Peter Falk, Chair of the Animal Hall of Fame Committee. This years exceptional inductees have made significant contributions to those around them.

A forever home for unwanted animals, a retired service dog, a floppy-eared snuggle bunny, an intuitive therapy horse and working police Bloodhound will be celebrated on March 11, 2018 with induction into the NJVMA Animal Hall of Fame.

Because of the internet and social media, stories involving the human-animal bond now reach well beyond state and even national boundaries and have the potential to prompt action on a global scale, Dr. Falk said.

Read more

Follow this link:
NJVMA | New Jersey Veterinary Medical Association

Read More...

biotechnology | Definition, Examples, & Applications …

June 26th, 2018 8:46 am

Biotechnology, the use of biology to solve problems and make useful products. The most prominent area of biotechnology is the production of therapeutic proteins and other drugs through genetic engineering.

People have been harnessing biological processes to improve their quality of life for some 10,000 years, beginning with the first agricultural communities. Approximately 6,000 years ago, humans began to tap the biological processes of microorganisms in order to make bread, alcoholic beverages, and cheese and to preserve dairy products. But such processes are not what is meant today by biotechnology, a term first widely applied to the molecular and cellular technologies that began to emerge in the 1960s and 70s. A fledgling biotech industry began to coalesce in the mid- to late 1970s, led by Genentech, a pharmaceutical company established in 1976 by Robert A. Swanson and Herbert W. Boyer to commercialize the recombinant DNA technology pioneered by Boyer and Stanley N. Cohen. Early companies such as Genentech, Amgen, Biogen, Cetus, and Genex began by manufacturing genetically engineered substances primarily for medical and environmental uses.

For more than a decade, the biotechnology industry was dominated by recombinant DNA technology, or genetic engineering. This technique consists of splicing the gene for a useful protein (often a human protein) into production cellssuch as yeast, bacteria, or mammalian cells in culturewhich then begin to produce the protein in volume. In the process of splicing a gene into a production cell, a new organism is created. At first, biotechnology investors and researchers were uncertain about whether the courts would permit them to acquire patents on organisms; after all, patents were not allowed on new organisms that happened to be discovered and identified in nature. But, in 1980, the U.S. Supreme Court, in the case of Diamond v. Chakrabarty, resolved the matter by ruling that a live human-made microorganism is patentable subject matter. This decision spawned a wave of new biotechnology firms and the infant industrys first investment boom. In 1982 recombinant insulin became the first product made through genetic engineering to secure approval from the U.S. Food and Drug Administration (FDA). Since then, dozens of genetically engineered protein medications have been commercialized around the world, including recombinant versions of growth hormone, clotting factors, proteins for stimulating the production of red and white blood cells, interferons, and clot-dissolving agents.

In the early years, the main achievement of biotechnology was the ability to produce naturally occurring therapeutic molecules in larger quantities than could be derived from conventional sources such as plasma, animal organs, and human cadavers. Recombinant proteins are also less likely to be contaminated with pathogens or to provoke allergic reactions. Today, biotechnology researchers seek to discover the root molecular causes of disease and to intervene precisely at that level. Sometimes this means producing therapeutic proteins that augment the bodys own supplies or that make up for genetic deficiencies, as in the first generation of biotech medications. (Gene therapyinsertion of genes encoding a needed protein into a patients body or cellsis a related approach.) But the biotechnology industry has also expanded its research into the development of traditional pharmaceuticals and monoclonal antibodies that stop the progress of a disease. Such steps are uncovered through painstaking study of genes (genomics), the proteins that they encode (proteomics), and the larger biological pathways in which they act.

In addition to the tools mentioned above, biotechnology also involves merging biological information with computer technology (bioinformatics), exploring the use of microscopic equipment that can enter the human body (nanotechnology), and possibly applying techniques of stem cell research and cloning to replace dead or defective cells and tissues (regenerative medicine). Companies and academic laboratories integrate these disparate technologies in an effort to analyze downward into molecules and also to synthesize upward from molecular biology toward chemical pathways, tissues, and organs.

In addition to being used in health care, biotechnology has proved helpful in refining industrial processes through the discovery and production of biological enzymes that spark chemical reactions (catalysts); for environmental cleanup, with enzymes that digest contaminants into harmless chemicals and then die after consuming the available food supply; and in agricultural production through genetic engineering.

Agricultural applications of biotechnology have proved the most controversial. Some activists and consumer groups have called for bans on genetically modified organisms (GMOs) or for labeling laws to inform consumers of the growing presence of GMOs in the food supply. In the United States, the introduction of GMOs into agriculture began in 1993, when the FDA approved bovine somatotropin (BST), a growth hormone that boosts milk production in dairy cows. The next year, the FDA approved the first genetically modified whole food, a tomato engineered for a longer shelf life. Since then, regulatory approval in the United States, Europe, and elsewhere has been won by dozens of agricultural GMOs, including crops that produce their own pesticides and crops that survive the application of specific herbicides used to kill weeds. Studies by the United Nations, the U.S. National Academy of Sciences, the European Union, the American Medical Association, U.S. regulatory agencies, and other organizations have found GMO foods to be safe, but skeptics contend that it is still too early to judge the long-term health and ecological effects of such crops. In the late 20th and early 21st centuries, the land area planted in genetically modified crops increased dramatically, from 1.7 million hectares (4.2 million acres) in 1996 to 160 million hectares (395 million acres) by 2011.

Overall, the revenues of U.S. and European biotechnology industries roughly doubled over the five-year period from 1996 through 2000. Rapid growth continued into the 21st century, fueled by the introduction of new products, particularly in health care.

See original here:
biotechnology | Definition, Examples, & Applications ...

Read More...

Plant genetics – Wikipedia

June 26th, 2018 8:45 am

Plant genetics is the study of genes, genetic variation, and heredity specifically in Plants.[1][2] It is generally considered a field of biology and botany, but intersects frequently with many other life sciences and is strongly linked with the study of information systems. Plant genetics is similar in many ways to animal genetics but differs in a few key areas.

The discoverer of genetics is Gregor Mendel, a late 19th-century scientist and Augustinian friar. Mendel studied "trait inheritance", patterns in the way traits are handed down from parents to offspring. He observed that organisms (pea plants) inherit traits by way of discrete "units of inheritance". This term, still used today, is a somewhat ambiguous definition of what is referred to as a gene. Much of Mendel's work with plants still forms the basis for modern plant genetics.

Plants, like all known organisms, use DNA to pass on their traits. Animal genetics often focuses on parentage and lineage, but this can sometimes be difficult in plant genetics due to the fact that plants can, unlike most animals, can self-fertilize. Speciation can be easier in many plants due to unique genetic abilities, such as being well adapted to polyploidy. Plants are unique in that they are able to make their own food via photosynthesis, a process which is achieved by use of a structure mostly exclusive to plants: chloroplasts. Chloroplasts, like the superficially similar mitochondria, possess their own DNA. Chloroplasts thus provide an additional reservoir for genes and genetic diversity, and an extra layer of genetic complexity not found in animals.

The study of plant genetics has major economic impacts: many staple crops are genetically modified to increase yields, confer pest and disease resistance, provide resistance to herbicides, or to increase their nutritional value.

The field of plant genetics began with the work of Gregor Mendel, who is often called the "father of genetics". He was an Augustinian priest and scientist born on 20 July 1822 in Austria-Hungary. He worked at the Abbey of St. Thomas in Brno , where his organism of choice for studying inheritance and traits was the pea plant. Mendel's work tracked many phenotypic traits of pea plants, such as their height, flower color, and seed characteristics. Mendel showed that the inheritance of these traits follows particular laws, which were later named after him. His seminal work on genetics was published in 1866, but went almost entirely unnoticed until 1900. Mendel died in 1884. The significance of Mendel's work was not recognized until the turn of the 20th century. Its rediscovery prompted the foundation of modern genetics.

Deoxyribonucleic acid (DNA) is a nucleic acid that contains the genetic instructions used in the development and functioning of all known living organisms and some viruses. The main role of DNA molecules is the long-term storage of information. DNA is often compared to a set of blueprints or a recipe, or a code, since it contains the instructions needed to construct other components of cells, such as proteins and RNA molecules. The DNA segments that carry this genetic information are called genes, but other DNA sequences have structural purposes, or are involved in regulating the use of this genetic information. Geneticists, including plant geneticists, use this sequencing of DNA to their advantage as they splice and delete certain genes and regions of the DNA molecule to produce a different or desired genotype and thus, also producing a different phenotype.

Plants, like all other known living organisms, pass on their traits using DNA. Plants however are unique from other living organisms in the fact that they have Chloroplasts. Like mitochondria, chloroplasts have their own DNA. Like animals, plants experience somatic mutations regularly, but these mutations can contribute to the germ line with ease, since flowers develop at the ends of branches composed of somatic cells. People have known of this for centuries, and mutant branches are called "sports". If the fruit on the sport is economically desirable, a new cultivar may be obtained.

Some plant species are capable of self-fertilization, and some are nearly exclusively self-fertilizers. This means that a plant can be both mother and father to its offspring, a rare occurrence in animals. Scientists and hobbyists attempting to make crosses between different plants must take special measures to prevent the plants from self-fertilizing. In plant breeding, people create hybrids between plant species for economic and aesthetic reasons. For example, the yield of Corn has increased nearly five-fold in the past century due in part to the discovery and proliferation of hybrid corn varieties.[3] Plant genetics can be used to predict which combination of plants may produce a plant with Hybrid vigor, or conversely many discoveries in Plant genetics have come from studying the effects of hybridization.

Plants are generally more capable of surviving, and indeed flourishing, as polyploids. Polyploid organisms have more than two sets of homologous chromosomes. For example, humans have two sets of homologous chromosomes, meaning that a typical human will have 2 copies each of 23 different chromosomes, for a total of 46. Wheat on the other hand, while having only 7 distinct chromosomes, is considered a hexaploid and has 6 copies of each chromosome, for a total of 42.[4] In animals, inheritable germline polyploidy is less common, and spontaneous chromosome increases may not even survive past fertilization. In plants however this is no such problem, polyploid individuals are created frequently by a variety of processes, however once created usually cannot cross back to the parental type. Polyploid individuals, if capable of self-fertilizing, can give rise to a new genetically distinct lineage, which can be the start of a new species. This is often called "instant speciation". Polyploids generally have larger fruit, an economically desirable trait, and many human food crops, including wheat, maize, potatoes, peanuts,[5] strawberries and tobacco, are either accidentally or deliberately created polyploids.

Arabidopsis thaliana, also known as thale cress, has been the model organism for the study of plant genetics. As Drosphila, a species of fruit fly, was to the understanding of early genetics, so has been arabidopsis to the understanding of plant genetics.

Genetically modified (GM) foods are produced from organisms that have had changes introduced into their DNA using the methods of genetic engineering. Genetic engineering techniques allow for the introduction of new traits as well as greater control over traits than previous methods such as selective breeding and mutation breeding.[6]

Genetically modifying plants is an important economic activity: in 2017, 89% of corn, 94% of soybeans, and 91% of cotton produced in the US were from genetically modified strains[7]. Since the introduction of GM crops, yields have increased by 22%, and profits have increased to farmers, especially in the developing world, by 68%. An important side effect of GM crops has been decreased land requirements, [8]

Commercial sale of genetically modified foods began in 1994, when Calgene first marketed its unsuccessful Flavr Savr delayed-ripening tomato.[9][10] Most food modifications have primarily focused on cash crops in high demand by farmers such as soybean, corn, canola, and cotton. Genetically modified crops have been engineered for resistance to pathogens and herbicides and for better nutrient profiles.[11] Other such crops include the economically important GM papaya which are resistant to the highly destructive Papaya ringspot virus, and the nutritionally improved golden rice (it is however still in development).[12]

There is a scientific consensus[13][14][15][16] that currently available food derived from GM crops poses no greater risk to human health than conventional food,[17][18][19][20][21] but that each GM food needs to be tested on a case-by-case basis before introduction.[22][23] Nonetheless, members of the public are much less likely than scientists to perceive GM foods as safe.[24][25][26][27] The legal and regulatory status of GM foods varies by country, with some nations banning or restricting them, and others permitting them with widely differing degrees of regulation.[28][29][30][31] There are still ongoing public concerns related to food safety, regulation, labeling, environmental impact, research methods, and the fact that some GM seeds are subject to intellectual property rights owned by corporations.[32]

Genetic modification has been the cause for much research into modern plant genetics, and has also lead to the sequencing of many plant genomes. Today there are two predominant procedures of transforming genes in organisms: the "Gene gun" method and the Agrobacterium method.

The gene gun method is also referred to as "biolistics" (ballistics using biological components). This technique is used for in vivo (within a living organism) transformation and has been especially useful in monocot species like corn and rice.This approach literally shoots genes into plant cells and plant cell chloroplasts. DNA is coated onto small particles of gold or tungsten approximately two micrometres in diameter. The particles are placed in a vacuum chamber and the plant tissue to be engineered is placed below the chamber. The particles are propelled at high velocity using a short pulse of high pressure helium gas, and hit a fine mesh baffle placed above the tissue while the DNA coating continues into any target cell or tissue.

Transformation via Agrobacterium has been successfully practiced in dicots, i.e. broadleaf plants, such as soybeans and tomatoes, for many years. Recently it has been adapted and is now effective in monocots like grasses, including corn and rice. In general, the Agrobacterium method is considered preferable to the gene gun, because of a greater frequency of single-site insertions of the foreign DNA, which allows for easier monitoring. In this method, the tumor inducing (Ti) region is removed from the T-DNA (transfer DNA) and replaced with the desired gene and a marker, which is then inserted into the organism. This may involve direct inoculation of the tissue with a culture of transformed Agrobacterium, or inoculation following treatment with micro-projectile bombardment, which wounds the tissue.[33] Wounding of the target tissue causes the release of phenolic compounds by the plant, which induces invasion of the tissue by Agrobacterium. Because of this, microprojectile bombardment often increases the efficiency of infection with Agrobacterium. The marker is used to find the organism which has successfully taken up the desired gene. Tissues of the organism are then transferred to a medium containing an antibiotic or herbicide, depending on which marker was used. The Agrobacterium present is also killed by the antibiotic. Only tissues expressing the marker will survive and possess the gene of interest. Thus, subsequent steps in the process will only use these surviving plants. In order to obtain whole plants from these tissues, they are grown under controlled environmental conditions in tissue culture. This is a process of a series of media, each containing nutrients and hormones. Once the plants are grown and produce seed, the process of evaluating the progeny begins. This process entails selection of the seeds with the desired traits and then retesting and growing to make sure that the entire process has been completed successfully with the desired results.

Domingo, Jos L.; Bordonaba, Jordi Gin (2011). "A literature review on the safety assessment of genetically modified plants" (PDF). Environment International. 37: 734742. doi:10.1016/j.envint.2011.01.003. PMID21296423.

Krimsky, Sheldon (2015). "An Illusory Consensus behind GMO Health Assessment" (PDF). Science, Technology, & Human Values. 40: 132. doi:10.1177/0162243915598381.

And contrast:

Panchin, Alexander Y.; Tuzhikov, Alexander I. (January 14, 2016). "Published GMO studies find no evidence of harm when corrected for multiple comparisons". Critical Reviews in Biotechnology: 15. doi:10.3109/07388551.2015.1130684. PMID26767435.

and

Yang, Y.T.; Chen, B. (2016). "Governing GMOs in the USA: science, law and public health". Journal of the Science of Food and Agriculture. 96: 18511855. doi:10.1002/jsfa.7523. PMID26536836.

Pinholster, Ginger (October 25, 2012). "AAAS Board of Directors: Legally Mandating GM Food Labels Could "Mislead and Falsely Alarm Consumers"". American Association for the Advancement of Science. Retrieved February 8, 2016.

Go here to read the rest:
Plant genetics - Wikipedia

Read More...

Analysts Set $4.35 Price Target for Fulgent Genetics Inc …

June 26th, 2018 8:45 am

Fulgent Genetics Inc (NASDAQ:FLGT) has been assigned a consensus broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating.

Brokers have set a 1 year consensus price objective of $4.35 for the company and are anticipating that the company will post ($0.05) EPS for the current quarter, according to Zacks. Zacks has also given Fulgent Genetics an industry rank of 70 out of 255 based on the ratings given to related companies.

Several equities analysts have recently weighed in on FLGT shares. Credit Suisse Group decreased their price target on shares of Fulgent Genetics from $6.50 to $6.00 and set an outperform rating on the stock in a research note on Thursday, March 1st. Piper Jaffray Companies downgraded shares of Fulgent Genetics from an overweight rating to a neutral rating in a research note on Thursday, March 1st. Finally, ValuEngine raised shares of Fulgent Genetics from a sell rating to a hold rating in a research note on Wednesday, May 2nd.

Shares of Fulgent Genetics traded down $0.27, hitting $4.19, during midday trading on Friday, MarketBeat.com reports. The companys stock had a trading volume of 11,472 shares, compared to its average volume of 12,262. The company has a market cap of $79.79 million, a P/E ratio of -38.09 and a beta of 0.28. Fulgent Genetics has a 12-month low of $2.72 and a 12-month high of $7.04.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings results on Monday, May 7th. The company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters consensus estimate of ($0.04) by ($0.02). The business had revenue of $4.65 million during the quarter. Fulgent Genetics had a negative return on equity of 7.62% and a negative net margin of 26.57%. analysts expect that Fulgent Genetics will post -0.29 earnings per share for the current year.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes.

Get a free copy of the Zacks research report on Fulgent Genetics (FLGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Continued here:
Analysts Set $4.35 Price Target for Fulgent Genetics Inc ...

Read More...

Myriad Genetics (MYGN) versus Quotient (QTNT) Head-To-Head …

June 26th, 2018 8:45 am

Myriad Genetics (NASDAQ: MYGN) and Quotient (NASDAQ:QTNT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.

Risk & Volatility

Myriad Genetics has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Quotient has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500.

This table compares Myriad Genetics and Quotients net margins, return on equity and return on assets.

Insider & Institutional Ownership

61.5% of Quotient shares are owned by institutional investors. 6.7% of Myriad Genetics shares are owned by company insiders. Comparatively, 29.0% of Quotient shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Myriad Genetics and Quotient, as reported by MarketBeat.

Myriad Genetics currently has a consensus price target of $30.91, suggesting a potential downside of 20.48%. Quotient has a consensus price target of $11.50, suggesting a potential upside of 30.68%. Given Quotients stronger consensus rating and higher probable upside, analysts plainly believe Quotient is more favorable than Myriad Genetics.

Earnings and Valuation

This table compares Myriad Genetics and Quotients gross revenue, earnings per share and valuation.

Myriad Genetics has higher revenue and earnings than Quotient. Quotient is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Summary

Myriad Genetics beats Quotient on 8 of the 13 factors compared between the two stocks.

About Myriad Genetics

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer. In addition, the company offers myPath Melanoma, a RNA expression test for diagnosing melanoma; myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency; and GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. Further, it provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.

About Quotient

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. It also develops, manufactures, and commercializes conventional reagent products for blood grouping, including antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company sells its products to donor collection agencies and testing laboratories, hospitals, independent patient testing laboratories, reference laboratories, blood banking operations, and other diagnostic companies, as well as to original equipment manufacturers. Quotient Limited was founded in 2007 and is based in Penicuik, the United Kingdom.

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post:
Myriad Genetics (MYGN) versus Quotient (QTNT) Head-To-Head ...

Read More...

Arthritis – Diagnosis and treatment – Mayo Clinic

June 26th, 2018 8:44 am

Diagnosis

During the physical exam, your doctor will check your joints for swelling, redness and warmth. He or she will also want to see how well you can move your joints. Depending on the type of arthritis suspected, your doctor may suggest some of the following tests.

The analysis of different types of body fluids can help pinpoint the type of arthritis you may have. Fluids commonly analyzed include blood, urine and joint fluid. To obtain a sample of your joint fluid, your doctor will cleanse and numb the area before inserting a needle in your joint space to withdraw some fluid (aspiration).

These types of tests can detect problems within your joint that may be causing your symptoms. Examples include:

Arthritis treatment focuses on relieving symptoms and improving joint function. You may need to try several different treatments, or combinations of treatments, before you determine what works best for you.

The medications used to treat arthritis vary depending on the type of arthritis. Commonly used arthritis medications include:

Physical therapy can be helpful for some types of arthritis. Exercises can improve range of motion and strengthen the muscles surrounding joints. In some cases, splints or braces may be warranted.

If conservative measures don't help, your doctor may suggest surgery, such as:

Explore Mayo Clinic studies testing new treatments, interventions and tests as a means to prevent, detect, treat or manage this disease.

In many cases, arthritis symptoms can be reduced with the following measures:

Many people use alternative remedies for arthritis, but there is little reliable evidence to support the use of many of these products. The most promising alternative remedies for arthritis include:

While you might first discuss your symptoms with your family doctor, he or she may refer you to a doctor who specializes in the treatment of joint problems (rheumatologist) for further evaluation.

Before your appointment, make a list that includes:

Your doctor may ask some of the following questions:

Read more from the original source:
Arthritis - Diagnosis and treatment - Mayo Clinic

Read More...

The 5 Worst Foods To For Arthritis – Natural Health Reports

June 26th, 2018 8:44 am

This video player is not support on your device, please click HERE to try a different player. We apologize for this inconvenience.

How long would YOU like to be pain free?

Look, I know you're skeptical. You should be. Look at all the big drug companies who are lying to you each and every day trying to convince you that their dangerous (sometimes deadly!) drugs are safe.

So I thought there's no better way for you to find out if Heal-n-Soothe will work for you, than having you try it. And that's why I'd like to send you a 90 count bottle, a 30 day supply, for free. You just pay the shipping and handling.

No matter what your arthritis pain level and frequency, fill out the risk-free acceptance form below to see how well Heal-n-Soothe Arthritis will work for you.

STEP 1: Where Should We Ship Your FREE Bottle?

Country *

Choose your country AFGHANISTANALBANIAALGERIAAMERICAN SAMOAANDORRAANGOLAANGUILLAANTARCTICAANTIGUA AND BARBUDAARGENTINAARMENIAARUBAAUSTRALIAAUSTRIAAZERBAIJANBAHAMASBAHRAINBANGLADESHBARBADOSBELARUSBELGIUMBELIZEBENINBERMUDABHUTANBOLIVIABOSNIA AND HERZEGOVINABOTSWANABOUVET ISLANDBRAZILBRITISH INDIAN OCEAN TERRITORYBRUNEI DARUSSALAMBULGARIABURKINA FASOBURUNDICAMBODIACAMEROONCANADACAPE VERDECAYMAN ISLANDSCENTRAL AFRICAN REPUBLICCHADCHILECHINACHRISTMAS ISLANDCOCOS (KEELING) ISLANDSCOLOMBIACOMOROSCONGOCONGO, THE DEMOCRATIC REPUBLIC OF THECOOK ISLANDSCOSTA RICACOTE D'IVOIRECROATIACUBACYPRUSCZECH REPUBLICDENMARKDJIBOUTIDOMINICADOMINICAN REPUBLICECUADOREGYPTEL SALVADOREQUATORIAL GUINEAERITREAESTONIAETHIOPIAFALKLAND ISLANDS (MALVINAS)FAROE ISLANDSFIJIFINLANDFRANCEFRENCH GUIANAFRENCH POLYNESIAFRENCH SOUTHERN TERRITORIESGABONGAMBIAGEORGIAGERMANYGHANAGIBRALTARGREECEGREENLANDGRENADAGUADELOUPEGUAMGUATEMALAGUINEAGUINEA-BISSAUGUYANAHAITIHEARD ISLAND AND MCDONALD ISLANDSHOLY SEE (VATICAN CITY STATE)HONDURASHONG KONGHUNGARYICELANDINDIAINDONESIAIRAN, ISLAMIC REPUBLIC OFIRAQIRELANDISRAELITALYJAMAICAJAPANJORDANKAZAKHSTANKENYAKIRIBATIKOREA, DEMOCRATIC PEOPLE'S REPUBLIC OFKOREA, REPUBLIC OFKUWAITKYRGYZSTANLAO PEOPLE'S DEMOCRATIC REPUBLICLATVIALEBANONLESOTHOLIBERIALIBYAN ARAB JAMAHIRIYALIECHTENSTEINLITHUANIALUXEMBOURGMACAOMACEDONIA, THE FORMER YUGOSLAV REPUBLIC OFMADAGASCARMALAWIMALAYSIAMALDIVESMALIMALTAMARSHALL ISLANDSMARTINIQUEMAURITANIAMAURITIUSMAYOTTEMEXICOMICRONESIA, FEDERATED STATES OFMOLDOVA, REPUBLIC OFMONACOMONGOLIAMONTSERRATMOROCCOMOZAMBIQUEMYANMARNAMIBIANAURUNEPALNETHERLANDSNETHERLANDS ANTILLESNEW CALEDONIANEW ZEALANDNICARAGUANIGERNIGERIANIUENORFOLK ISLANDNORTHERN MARIANA ISLANDSNORWAYOMANPAKISTANPALAUPALESTINIAN TERRITORY, OCCUPIEDPANAMAPAPUA NEW GUINEAPARAGUAYPERUPHILIPPINESPITCAIRNPOLANDPORTUGALPUERTO RICOQATARREUNIONROMANIARUSSIAN FEDERATIONRWANDASAINT HELENASAINT KITTS AND NEVISSAINT LUCIASAINT PIERRE AND MIQUELONSAINT VINCENT AND THE GRENADINESSAMOASAN MARINOSAO TOME AND PRINCIPESAUDI ARABIASENEGALSERBIA AND MONTENEGROSEYCHELLESSIERRA LEONESINGAPORESLOVAKIASLOVENIASOLOMON ISLANDSSOMALIASOUTH AFRICASOUTH GEORGIA AND THE SOUTH SANDWICH ISLANDSSPAINSRI LANKASUDANSURINAMESVALBARD AND JAN MAYENSWAZILANDSWEDENSWITZERLANDSYRIAN ARAB REPUBLICTAIWAN, PROVINCE OF CHINATAJIKISTANTANZANIA, UNITED REPUBLIC OFTHAILANDTIMOR-LESTETOGOTOKELAUTONGATRINIDAD AND TOBAGOTUNISIATURKEYTURKMENISTANTURKS AND CAICOS ISLANDSTUVALUUGANDAUKRAINEUNITED ARAB EMIRATESUNITED KINGDOMUNITED STATESUNITED STATES MINOR OUTLYING ISLANDSURUGUAYUZBEKISTANVANUATUVENEZUELAVIET NAMVIRGIN ISLANDS, BRITISHVIRGIN ISLANDS, U.S.WALLIS AND FUTUNAWESTERN SAHARAYEMENZAMBIAZIMBABWE

State *

Choose your state AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUSAF, AmericasUSAF, EuropeUSAF, PacificUtahVermontVirginiaWashingtonWashington DCWest VirginiaWisconsinWyoming

Get Your FREE Bottle

Learn about the trouble making vegetable, YES VEGETABLE... that can make your Arthritis worse. (And Make you feel 5 - 10 years older.)

The secret switch inside your body that you can flip to help make it start acting like it did when you were 25 years old.

The real reason why pain killers don't help your pain.

Which special superfood can actually counteract the damage or arthritis.

Adler A, Holub B. Effect of garlic and fish-oil supplementation on serum lipid and lipoprotein concentrations in hypercholesterolemic men. American Journal of Clinical Nutrition. 1997 Feb;65(2):445-50.

NIAMS, NIH, Bethesda, Maryland 20892, USA. Arthritis & Rheumatology (Impact Factor: 7.87).06/1998; 41(5):778-99. DOI: 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V Source: PubMed

Hrlimann, David, Frank Enseleit, and Priv-Doz Dr Frank Ruschitzka. Rheumatoide arthritis, inflammation und atherosklerose. Herz 29.8 (2004): 760-768.

Schett, Georg. Rheumatoid arthritis: inflammation and bone loss. Wiener Medizinische Wochenschrift 156.1-2 (2006): 34-41.

More here:
The 5 Worst Foods To For Arthritis - Natural Health Reports

Read More...

About Us American Board of Preventive Medicine

June 26th, 2018 8:44 am

What is Preventive Medicine?

Preventive Medicine is the specialty of medical practice that focuses on the health of individuals, communities, and defined populations. Its goal is to protect, promote, and maintain health and well-being and to prevent disease, disability, and death, Preventive medicine specialists have core competencies in biostatistics, epidemiology, environmental and occupational medicine, planning and evaluation of health services, management of healthcare organizations, research into causes of disease and injury in population groups, and the practice of prevention in clinical medicine. They apply knowledge and skills gained from the medical, social, economic, and behavioral sciences.

Preventive medicine has three specialty areas with common core knowledge, skills, and competencies that emphasize different populations, environments, or practice settings:

Preventive medicine also encompasses 4 subspecialty areas, including:

The purpose of the American Board of Preventive Medicine is:

View board members

The American Board of Preventive Medicine, Inc. (ABPM) is a member board of the American Board of Medical Specialties. ABPM originated from recommendations of a joint committee comprised of representatives from the Section of Preventive and Industrial Medicine and Public Health of the American Medical Association and the Committee on Professional Education of the American Public Health Association. The Board was incorporated under the laws of the State of Delaware on June 29, 1948 as The American Board of Preventive Medicine and Public Health, Incorporated.

In 1952 the name was changed to The American Board of Preventive Medicine, Inc. In February 1953, the Advisory Board of Medical Specialties and the Council on Medical Education and Hospitals of the American Medical Association authorized certification by the Board of preventive medicine specialists in Aviation Medicine (the name was changed to Aerospace Medicine in 1963); in June 1955, preventive medicine specialists in Occupational Medicine; in November 1960, preventive medicine specialists in General Preventive Medicine; and in 1983, Public Health and General Preventive Medicine were combined into one specialty area of certification. In 1989 the American Board of Preventive Medicine was approved to offer a subspecialty certificate in Undersea Medicine (the name was changed to Undersea and Hyperbaric Medicine in 1999), in 1992 a subspecialty certificate in Medical Toxicology, in 2010 a subspecialty certificate in Clinical Informatics, and in 2017 a subspecialty in Addiction Medicine.

The Board is a non-profit corporation, and no member (officer or director) may receive any salary or compensation for services. The Board consists of members nominated by the organizations listed below:

More here:
About Us American Board of Preventive Medicine

Read More...

Page 907«..1020..906907908909..920930..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick